HDAC2

Summary

HDAC2 (histone deacetylase 2, HGNC:4853) is a protein-coding gene on chromosome 6q21, encoding Histone deacetylase 2 (Q92769). Histone deacetylase that catalyzes the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4).

This gene product belongs to the histone deacetylase family. Histone deacetylases act via the formation of large multiprotein complexes, and are responsible for the deacetylation of lysine residues at the N-terminal regions of core histones (H2A, H2B, H3 and H4). This protein forms transcriptional repressor complexes by associating with many different proteins, including YY1, a mammalian zinc-finger transcription factor. Thus, it plays an important role in transcriptional regulation, cell cycle progression and developmental events. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 3066 — RefSeq curated summary.

At a glance

• Gene–disease (curated): complex neurodevelopmental disorder (Limited, GenCC)
• GWAS associations: 3
• Clinical variants (ClinVar): 63 total
• Regional missense constraint (gnomAD): 1 of 2 regions constrained (≈79% of expected missense variation)
• GTEx eGene: eQTL in 10 tissues, sQTL in 13 (q < 0.05)
• Drug target: yes — 2 curated mechanism-of-action drugs; 41 molecules with ChEMBL bioactivity (top 1% of genes corpus-wide)
• Approved drugs (ChEMBL mechanism of action): 1 — Vorinostat
• Constraint (gnomAD): pLI 0.99 (loss-of-function intolerant), LOEUF 0.37 (moderately constrained)
• Transcription factor: yes — 28 downstream targets (CollecTRI)
• MANE Select transcript: NM_001527
• Interaction hub: 4,548 STRING partners (top 1% of genes corpus-wide)
• Notable: 63 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4853
Approved symbol	HDAC2
Name	histone deacetylase 2
Location	6q21
Locus type	gene with protein product
Status	Approved
Aliases	RPD3, YAF1, KDAC2
Ensembl gene	ENSG00000196591
Ensembl biotype	protein_coding
OMIM	605164
Entrez	3066

Gene structure

Transcript identifiers

Ensembl transcripts: 42 — 30 protein_coding, 7 nonsense_mediated_decay, 5 retained_intron

MANE Select: ENST00000519065

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1, TSL 2: 6, TSL 3: 2, TSL 4: 5, TSL 5: 3

ENST00000519065, ENST00000368632, ENST00000425835, ENST00000518690, ENST00000518756, ENST00000519108, ENST00000520170, ENST00000520746, ENST00000520895, ENST00000521163, ENST00000521233, ENST00000521610, ENST00000522371, ENST00000523240, ENST00000523334, ENST00000523628, ENST00000524334, ENST00000869750, ENST00000869751, ENST00000869752, ENST00000916845, ENST00000916846, ENST00000916847, ENST00000916848, ENST00000916849, ENST00000916850, ENST00000916851, ENST00000952494, ENST00000982557, ENST00001027009, ENST00001027013, ENST00001027015, ENST00001027017, ENST00001075886, ENST00001075888, ENST00001075890, ENST00001075891, ENST00001075897, ENST00001109491, ENST00001109492, ENST00001112880, ENST00001134871

RefSeq mRNA: 1 — MANE Select: NM_001527 NM_001527

CCDS: CCDS43493

Canonical transcript exons

ENST00000519065 — 14 exons

Exon	Start	End
ENSE00000975531	113958649	113958766
ENSE00000975532	113956619	113956693
ENSE00001084361	113949168	113949260
ENSE00002092091	113933028	113941088
ENSE00002133903	113970857	113971148
ENSE00003497597	113944280	113944410
ENSE00003529625	113959906	113960018
ENSE00003533415	113943351	113943506
ENSE00003545171	113941708	113941765
ENSE00003565277	113953277	113953418
ENSE00003585974	113946008	113946148
ENSE00003665730	113956013	113956151
ENSE00003675004	113948979	113949087
ENSE00003675635	113945362	113945470

Expression profiles

Bgee: expression breadth ubiquitous, 295 present calls, max score 99.55.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 87.3119 / max 506.2534, expressed in 1824 samples.

Highest expression (Bgee): ganglionic eminence, cortical plate, embryo, ventricular zone, primordial germ cell in gonad.

Genetic regulation across tissues (GTEx eQTL / sQTL)

HDAC2 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 10 tissues and its splicing (sQTL) in 13 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 23 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Testis	sqtl	7.5e-14	-0.87	6:113940688:T:C
Adipose Subcutaneous	sqtl	2.8e-09	+0.59	6:113962399:A:G
Lung	sqtl	2.5e-04	+0.49	6:113940688:T:C
Brain Nucleus accumbens basal ganglia	eqtl	7.8e-04	+0.20	6:113921255:T:C
Brain Caudate basal ganglia	eqtl	1.2e-03	+0.18	6:113976574:G:A
Nerve Tibial	sqtl	1.5e-03	+0.36	6:113914950:A:G
Colon Transverse	sqtl	1.7e-03	-0.49	6:113962399:A:G
Esophagus Muscularis	sqtl	2.1e-03	+0.35	6:113979854:T:A
Brain Anterior cingulate cortex BA24	sqtl	3.1e-03	-0.61	6:113921735:T:C
Thyroid	sqtl	4.9e-03	+0.39	6:113962399:A:G
Breast Mammary Tissue	sqtl	5.9e-03	-0.44	6:113914950:A:G
Muscle Skeletal	eqtl	7.4e-03	+0.12	6:113914597:C:CT
Thyroid	eqtl	1.0e-02	-0.14	6:113914717:G:T
Brain Caudate basal ganglia	sqtl	1.5e-02	-0.49	6:113984661:G:A
Adipose Subcutaneous	eqtl	1.7e-02	+0.14	6:114124689:A:T
Artery Tibial	eqtl	1.7e-02	+0.07	6:114005766:C:T
Brain Nucleus accumbens basal ganglia	sqtl	2.0e-02	-0.55	6:113962224:A:T
Brain Cerebellar Hemisphere	eqtl	2.2e-02	-0.92	6:113902487:G:A
Brain Cortex	sqtl	2.6e-02	-0.46	6:113914225:T:C
Testis	eqtl	2.7e-02	-0.37	6:114804529:G:A

FANTOM5 promoters

5 alternative TSS:

Promoter ID	TPM avg	Samples expressed
75222	81.7831	1823
75221	2.8869	1169
75224	1.7796	805
75225	0.4323	235
75223	0.4300	240

Top tissues by expression

showing 100 of 295 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ganglionic eminence	UBERON:0004023	99.55	gold quality
cortical plate	UBERON:0005343	99.54	gold quality
embryo	UBERON:0000922	99.25	gold quality
ventricular zone	UBERON:0003053	99.15	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	98.72	gold quality
stromal cell of endometrium	CL:0002255	97.91	gold quality
adrenal tissue	UBERON:0018303	97.34	gold quality
right testis	UBERON:0004534	97.10	gold quality
islet of Langerhans	UBERON:0000006	96.89	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	96.84	gold quality
testis	UBERON:0000473	96.73	gold quality
left testis	UBERON:0004533	96.69	gold quality
rectum	UBERON:0001052	96.34	gold quality
right ovary	UBERON:0002118	96.23	gold quality
left ovary	UBERON:0002119	96.18	gold quality
endometrium	UBERON:0001295	96.15	gold quality
ovary	UBERON:0000992	96.10	gold quality
body of uterus	UBERON:0009853	95.97	gold quality
smooth muscle tissue	UBERON:0001135	95.93	gold quality
body of pancreas	UBERON:0001150	95.88	gold quality
left uterine tube	UBERON:0001303	95.85	gold quality
ectocervix	UBERON:0012249	95.85	gold quality
popliteal artery	UBERON:0002250	95.79	gold quality
tibial artery	UBERON:0007610	95.79	gold quality
endocervix	UBERON:0000458	95.76	gold quality
monocyte	CL:0000576	95.67	gold quality
pancreas	UBERON:0001264	95.59	gold quality
skin of abdomen	UBERON:0001416	95.55	gold quality
right coronary artery	UBERON:0001625	95.49	gold quality
aorta	UBERON:0000947	95.44	gold quality
mononuclear cell	CL:0000842	95.37	gold quality
skin of leg	UBERON:0001511	95.31	gold quality
leukocyte	CL:0000738	95.28	gold quality
muscle layer of sigmoid colon	UBERON:0035805	95.24	gold quality
right adrenal gland	UBERON:0001233	95.23	gold quality
vagina	UBERON:0000996	95.17	gold quality
descending thoracic aorta	UBERON:0002345	95.17	gold quality
esophagus mucosa	UBERON:0002469	95.17	gold quality
mucosa of transverse colon	UBERON:0004991	95.16	gold quality
left adrenal gland	UBERON:0001234	95.15	gold quality
left coronary artery	UBERON:0001626	95.09	gold quality
adenohypophysis	UBERON:0002196	95.08	gold quality
thoracic aorta	UBERON:0001515	95.06	gold quality
minor salivary gland	UBERON:0001830	95.06	gold quality
uterus	UBERON:0000995	95.04	gold quality
ascending aorta	UBERON:0001496	95.03	gold quality
right adrenal gland cortex	UBERON:0035827	95.03	gold quality
transverse colon	UBERON:0001157	95.02	gold quality
left adrenal gland cortex	UBERON:0035825	94.98	gold quality
right uterine tube	UBERON:0001302	94.95	gold quality
female reproductive system	UBERON:0000474	94.94	gold quality
esophagus	UBERON:0001043	94.85	gold quality
adrenal gland	UBERON:0002369	94.82	gold quality
zone of skin	UBERON:0000014	94.80	gold quality
sigmoid colon	UBERON:0001159	94.77	gold quality
body of stomach	UBERON:0001161	94.76	gold quality
coronary artery	UBERON:0001621	94.62	gold quality
gall bladder	UBERON:0002110	94.62	gold quality
adrenal cortex	UBERON:0001235	94.57	gold quality
lower esophagus	UBERON:0013473	94.55	gold quality
lower esophagus muscularis layer	UBERON:0035833	94.55	gold quality
right lung	UBERON:0002167	94.54	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	94.54	gold quality
calcaneal tendon	UBERON:0003701	94.52	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	94.49	gold quality
mouth mucosa	UBERON:0003729	94.47	gold quality
colon	UBERON:0001155	94.46	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	94.46	gold quality
pituitary gland	UBERON:0000007	94.44	gold quality
colonic epithelium	UBERON:0000397	94.43	gold quality
saliva-secreting gland	UBERON:0001044	94.42	gold quality
hindlimb stylopod muscle	UBERON:0004252	94.40	gold quality
tibial nerve	UBERON:0001323	94.39	gold quality
stomach	UBERON:0000945	94.38	gold quality
upper lobe of left lung	UBERON:0008952	94.38	gold quality
omental fat pad	UBERON:0010414	94.38	gold quality
mucosa of stomach	UBERON:0001199	94.37	gold quality
peritoneum	UBERON:0002358	94.37	gold quality
large intestine	UBERON:0000059	94.33	gold quality
amniotic fluid	UBERON:0000173	94.30	gold quality
sperm	CL:0000019	94.27	gold quality
metanephros cortex	UBERON:0010533	94.26	gold quality
tendon	UBERON:0000043	94.22	gold quality
intestine	UBERON:0000160	94.13	gold quality
small intestine Peyer’s patch	UBERON:0003454	94.11	gold quality
upper lobe of lung	UBERON:0008948	94.10	gold quality
male germ cell	CL:0000015	94.04	gold quality
vermiform appendix	UBERON:0001154	94.01	gold quality
adipose tissue of abdominal region	UBERON:0007808	94.01	gold quality
fallopian tube	UBERON:0003889	93.91	gold quality
lymph node	UBERON:0000029	93.90	gold quality
seminal vesicle	UBERON:0000998	93.85	gold quality
tibia	UBERON:0000979	93.84	gold quality
left lobe of thyroid gland	UBERON:0001120	93.83	gold quality
urinary bladder	UBERON:0001255	93.81	gold quality
gastrocnemius	UBERON:0001388	93.78	gold quality
right atrium auricular region	UBERON:0006631	93.62	gold quality
caudate nucleus	UBERON:0001873	93.61	gold quality
spinal cord	UBERON:0002240	93.59	gold quality
muscle of leg	UBERON:0001383	93.52	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-134144	yes	28.77
E-CURD-114	yes	8.70
E-MTAB-7303	no	474.39
E-GEOD-93593	no	7.31
E-ANND-3	no	0.00

HPA expression

RNA tissue specificity: Low tissue specificity

showing 60 of 80 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Caudate putamen	tissue	90.3
Frontal cortex	tissue	73.7
Testis	tissue	71.6	high
Thymus	tissue	63.8
Bone marrow	tissue	59.8	high
Nucleus accumbens	tissue	59.3
Urinary bladder	tissue	59.0	high
Cerebellum	tissue	56.8	high
Ovary	tissue	55.7	high
Basal ganglia	tissue	55.7	high
Putamen	tissue	55.7
Postcentral gyrus	tissue	55.2
Hippocampal formation	tissue	54.6
Endometrium 1	tissue	53.7	high
Thalamus	tissue	53.4
Placenta	tissue	52.6	high
Pons	tissue	52.1
Locus coeruleus	tissue	51.5
Breast	tissue	51.3	medium
Superior colliculi	tissue	50.8
Smooth muscle	tissue	50.7	high
Rectum	tissue	50.4	medium
Epididymis	tissue	50.4	high
Ventral forebrain	tissue	49.6
Septum	tissue	48.9
Tonsil	tissue	48.8	high
Olfactory bulb	tissue	48.1
Midbrain	tissue	47.7
Hippocampus	tissue	46.6	high
Fallopian tube	tissue	45.8	high
Cerebral cortex	tissue	45.6	high
Somatosensory cortex	tissue	45.6
Skeletal muscle	tissue	45.4	high
Colon	tissue	45.0	high
Motor cortex	tissue	44.9
Occipital cortex	tissue	44.3
Prostate	tissue	44.1	high
Skin 1	tissue	43.5	high
Kidney	tissue	43.1	high
Parathyroid gland	tissue	43.0	high
Thyroid gland	tissue	42.7	medium
Seminal vesicle	tissue	42.6	medium
Cervix	tissue	42.4	high
Prefrontal cortex	tissue	42.0
Retrosplenial and cingulate cortex	tissue	41.4
Choroid plexus	tissue	41.2
Entorhinal cortex	tissue	40.9
Hypothalamus	tissue	40.8
Tongue	tissue	40.5
Temporal cortex	tissue	40.5
Adrenal gland	tissue	40.3	high
Lymph node	tissue	39.8	high
Medulla oblongata	tissue	39.8
Esophagus	tissue	38.7	high
Heart muscle	tissue	38.5	high
Stomach 1	tissue	38.3	high
Spinal cord	tissue	38.0
Retrosplenial cortex	tissue	38.0
Periaqueductal gray	tissue	37.8
Vagina	tissue	36.2	medium

Brain sub-regions (HPA Brain Atlas): detected in 192; highest nTPM — Parieto-temporal junction (white matter) (70.5), Corpus callosum, splenium (white matter) (69.0), Paraventricular nucleus (67.1), Temporal white matter (65.9), Corpus callosum, genu (white matter) (64.5).

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

28 targets:

Target	Regulation
ALOX5	Activation
APAF1	Repression
BMP7	Repression
CAD	Unknown
CCL2	Unknown
CCNE1	Repression
CD1D	Repression
CDH1	Repression
CDKN1A	Unknown
COL1A2	Repression
CXCL8	Repression
DELEC1	Unknown
DNMT1	Repression
GRM2	Unknown
HPGD	Repression
IGF1	Unknown
KLF4	Repression
MUC5AC	Repression
MYC	Unknown
MYCN	Unknown
PHB1	Repression
SNAI2	Repression
SP1	Repression
TGFBR2	Repression
TNFSF10	Repression
TP63	Unknown
TWIST1	Repression
VEGFA	Unknown

Upstream regulators (CollecTRI, top): HIF1A, MYC, MYCN, RFX5, SFPQ, TP53, YY1

miRNA regulators (miRDB)

Targeting HDAC2 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 185 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-8485	100.00	77.57	4731
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-548AJ-3P	99.96	73.38	5345

Functional genomics

gnomAD constraint: pLI 0.989, LOEUF 0.367, missense Z 1.84 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD)

ENST00000519065 splits into 2 regions with different missense tolerance; 1 is missense-constrained (≈79% of the expected missense variation). Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD

Region (GRCh38)	Missense obs / exp	o/e	Constrained
6:113,941,061–113,944,358	137 / 128.7	1.06	no
6:113,944,359–113,970,908	154 / 472.1	0.33	yes (p 1.6e-48)

Literature-anchored findings (GeneRIF, showing 40)

• Phosphatase inhibition leads to histone deacetylases 1 and 2 phosphorylation and disruption of corepressor interactions (PMID:11919195)
• Regulation by protein kinase CK2 (PMID:12082111)
• Data show that Daxx associates with proteins critical for transcriptional repression, such as histone deacetylase 2 and Dek, a chromatin-associated protein reported to change the topology of DNA in chromatin in vitro. (PMID:12140263)
• HDAC2 is phosphorylated by CK2 and recruited by Sp1 or Sp3 (PMID:12176973)
• The MLL repression domain specifically interacts with HDAC2. (PMID:12829790)
• IkappaBalpha regulates the transcriptional activity of homeodomain-containing proteins positively through cytoplasmic sequestration of HDAC1 and HDAC3 (PMID:12972430)
• HDAC2 binds to HoxA10 and has a role in repressing gene transcription in undifferentiated myeloid cells (PMID:14512427)
• interaction of HPV type 31 E7 with HDACs and the integrity of the zinc finger-like motifs are essential for extending the life span of keratinocytes and for stable maintenance of viral genomes (PMID:15016876)
• Increased HDAC2 expression is associated with colon cancer (PMID:15144953)
• PELP1 recruits HDAC2 and masks histones using two separate domains (PMID:15456770)
• involved in the early events of carcinogenesis, so candidate marker for tumor progression, target for cancer therapy (PMID:15665816)
• A rationale for targeting HIF-1 alpha with histone dacetylase inhibitors against class II isozymes as anticancer agents in renal carcinoma cells. (PMID:16951198)
• Brg1 and HDAC2 have roles in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease (PMID:17043312)
• Transgenic HDAC2 regulates expression of many fetal cardiac isoforms, including glycogen synthase kinase 3 beta. (PMID:17322895)
• High expression of HDAC2 is associated with cancer tissues (PMID:17786334)
• unmodified HDAC2 is associated with the coding region of transcribed genes, whereas phosphorylated HDAC2 is primarily recruited to promoters (PMID:17827154)
• CK2 may be a key mediator for HDAC1 and HDAC2 activation under hypoxia in tumor cells (PMID:17935135)
• we showed that the known effects of HDACs on differentiation and proliferation of cancer cells observed in vitro can also be confirmed in vivo. The class I HDAC isoforms 1, 2 and 3 are differentially expressed in prostate cancer. (PMID:18212746)
• HDAC2 mutations have a role in human tumorigenesis through the derepression of key genes from multiple cellular transformation pathways (PMID:18264134)
• depletion of HDAC2 results in simultaneous depletion of ER and PR, and potentiates the effects of antihormonal therapy in ER-positive cells (PMID:18316616)
• Strong prognostic impact of HDAC isoforms in colorectal cancer. (PMID:18347167)
• LPA enhances survival of cancer cells by increasing HDAC1 and HDAC2 activity and reducing histone acetylation (PMID:18408217)
• High expression of HDAC2 is more common in aggressive than indolent cutaneous T-cell lymphoma. (PMID:18671804)
• Recruitment of HDAC-1 and -2 by TNF-alpha, and a consequent deacetylation of histone H3 at the YKL-40 promoter occurs only in glioma cells. (PMID:18708058)
• Frequent HDAC2 mutations are found in MSI tumors and HDAC2 plays a major role in mediating apoptotic response to HDAC inhibitors through direct regulation of APAF1. (PMID:18834886)
• In HCT116 cells, HDAC2 was shown to localize to the APAF1 promoter, and siRNA-mediated down-regulation of HDAC2 induced APAF1 expression, suggesting HDAC2 directly represses APAF1 expression. (PMID:18851967)
• class I histone deacetylase (HDACs), specifically HDAC2, and the transcriptional repressor Snail play a central role in the suppression of 15-hydroxyprostaglandin dehydrogenase expression. (PMID:19010907)
• P/CAF deacetylation by HDAC3 and in a minor degree by HDAC1, HDAC2, or HDAC4 leads to cytoplasmic accumulation of P/CAF. (PMID:19015268)
• TSA treatment enhances the association of CIITA with the transcription factor RFX5, which ameliorates the down-regulation of CIITA recruitment to target promoters by HDAC2. (PMID:19041327)
• the TGFbeta pathway activation leads to recruitment of a KLF14-mSin3A-HDAC2 repressor complex to the TGFbetaRII promoter, as well as the remodeling of chromatin to increase histone marks that associate with transcriptional silencing. (PMID:19088080)
• findings show class I HDAC isoforms 1 and 2 are highly expressed in renal cell cancer, while HDAC 3 shows low, histology dependent expression rates (PMID:19099586)
• Transcription analysis and genome-wide histone modification studies on these mutants suggested that K36me2 is sufficient to target Rpd3S in vivo, thereby maintaining a functional Set2-Rpd3S pathway. (PMID:19155214)
• Reduced levels of HDAC2 was associated with breast cancer progression. (PMID:19383825)
• nitration of distinct tyrosine residues modifies both the expression and activity of HDAC2, having an impact on epigenetic regulation. (PMID:19410558)
• Reduced HDAC2 and HDAC2 activity, but not HDAC2 mRNA, is observed in cells deficient in CFTR. (PMID:19411311)
• deletion of a single HDAC is not sufficient to induce cell death, but HDAC1 and 2 play redundant and essential roles in tumor cell survival (PMID:19416910)
• HDAC2, is overexpressed in diffuse large B-cell lymphoma and peripheral T-cell lymphoma relative to normal lymphoid tissue (PMID:19438744)
• IL-8 and MCP-1 were differently regulated by hypoxia. (PMID:19446037)
• HDAC2 also plays an important role in cell proliferation and apoptosis of rheumatoid arthritis synovial fibroblasts (PMID:19531758)
• The data indicate that the carboxy-terminal domain serves a novel function within HDAC1 and HDAC2, to mediate repression of cartilage-specific gene expression in human chondrocytes. (PMID:19561124)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
mus_musculus	Hdac2	ENSMUSG00000019777
rattus_norvegicus	Hdac2	ENSRNOG00000000604
drosophila_melanogaster	HDAC1	FBGN0015805
caenorhabditis_elegans		WBGENE00009657
caenorhabditis_elegans		WBGENE00009663
caenorhabditis_elegans		WBGENE00219378

Paralogs (10): HDAC9 (ENSG00000048052), HDAC7 (ENSG00000061273), HDAC4 (ENSG00000068024), HDAC6 (ENSG00000094631), HDAC10 (ENSG00000100429), HDAC5 (ENSG00000108840), HDAC1 (ENSG00000116478), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC3 (ENSG00000171720)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:1097691) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 48 distinct phenotype terms.

Mouse phenotype (MP)	Records
decreased body size	2
neonatal lethality, complete penetrance	2
prenatal lethality, incomplete penetrance	2
increased fetal cardiomyocyte proliferation	2
abnormal heart morphology	1
enlarged heart	1
abnormal intestinal mucosa morphology	1
abnormal dentate gyrus morphology	1
small testis	1
decreased body weight	1
unresponsive to tactile stimuli	1
abnormal cardiovascular system physiology	1
cyanosis	1
reduced fertility	1
abnormal cardiovascular system morphology	1
decreased brain weight	1
abnormal myocardial trabeculae morphology	1
thick ventricular wall	1
enhanced long-term potentiation	1
insensitivity to growth hormone	1
abnormal heart right ventricle morphology	1
embryonic growth retardation	1
diffuse Z line	1
abnormal pelvic girdle bone morphology	1
small vertebrae	1

+23 more (showing top 25).

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Staphylococcus aureus subsp. aureus Mu50	P64375	100.0%	Diamond
Staphylococcus aureus subsp. aureus N315	P64376	100.0%	Diamond
Pongo abelii	Q5RAG0	100.0%	Diamond
Staphylococcus aureus subsp. aureus MSSA476	Q6G8J2	100.0%	Diamond
Staphylococcus aureus subsp. aureus MW2	Q8NW34	100.0%	Diamond
Staphylococcus aureus subsp. aureus COL	Q5HF39	99.7%	Diamond
Bos taurus	Q32PJ8	99.6%	Diamond
Macaca fascicularis	Q9GKU5	99.1%	Diamond
Staphylococcus aureus subsp. aureus MRSA252	Q6GFX3	98.5%	Diamond
Xenopus tropicalis	Q28DV3	98.4%	Diamond
Xenopus laevis	Q6IRL9	98.4%	Diamond
Gallus gallus	P56519	98.2%	Diamond
Tetraodon nigroviridis	Q4SFA0	96.7%	Diamond
Danio rerio	Q803C3	96.7%	Diamond
Oryza sativa Japonica Group	Q6YV04	95.9%	Diamond
Arabidopsis thaliana	Q8H0W2	95.5%	Diamond
Strongylocentrotus purpuratus	P56518	86.9%	Diamond
Zea mays	P56521	81.5%	Diamond
Staphylococcus xylosus	Q56195	68.8%	Diamond
Dictyostelium discoideum	Q55FN5	67.1%	Diamond
Schizosaccharomyces pombe 972h-	O59702	66.6%	Diamond
Saccharomyces cerevisiae S288C	P32561	66.6%	Diamond
Bacillus subtilis subsp. subtilis str. 168	P39067	49.0%	Diamond
Burkholderia pseudomallei 1710b	Q3JUN4	43.5%	Diamond
Archaeoglobus fulgidus DSM 4304	O30107	40.8%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
HDAC2-AS2	ncRNA	101927768
HS3ST5	protein-coding	222537
LNCPOIR	ncRNA	105377959
LINC02880	ncRNA	285759
MROCKI	ncRNA	285758
MARCKS	protein-coding	4082

Protein

Protein identifiers

Histone deacetylase 2 — Q92769 (reviewed: Q92769)

Alternative names: Protein deacylase HDAC2

All UniProt accessions (10): E5RFI6, E5RFP9, E5RG37, E5RGV4, E5RH52, E5RHE7, E5RJ04, E5RK19, Q92769, H3BM24

UniProt curated annotations — full annotation on UniProt →

Function. Histone deacetylase that catalyzes the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Forms transcriptional repressor complexes by associating with MAD, SIN3, YY1 and N-COR. Component of a RCOR/GFI/KDM1A/HDAC complex that suppresses, via histone deacetylase (HDAC) recruitment, a number of genes implicated in multilineage blood cell development. Acts as a component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin. Component of the SIN3B complex that represses transcription and counteracts the histone acetyltransferase activity of EP300 through the recognition H3K27ac marks by PHF12 and the activity of the histone deacetylase HDAC2. Also deacetylates non-histone targets: deacetylates TSHZ3, thereby regulating its transcriptional repressor activity. May be involved in the transcriptional repression of circadian target genes, such as PER1, mediated by CRY1 through histone deacetylation. Involved in MTA1-mediated transcriptional corepression of TFF1 and CDKN1A. In addition to protein deacetylase activity, also acts as a protein-lysine deacylase by recognizing other acyl groups: catalyzes removal of (2E)-butenoyl (crotonyl), lactoyl (lactyl) and 2-hydroxyisobutanoyl (2-hydroxyisobutyryl) acyl groups from lysine residues, leading to protein decrotonylation, delactylation and de-2-hydroxyisobutyrylation, respectively.

Subunit / interactions. Part of the core histone deacetylase (HDAC) complex composed of HDAC1, HDAC2, RBBP4 and RBBP7, the core complex associates with SIN3, SAP18 and SAP30 to form the SIN3 HDAC complex. Component of the nucleosome remodeling and deacetylase (NuRD) repressor complex, composed of core proteins MTA1, MTA2, MTA3, RBBP4, RBBP7, HDAC1, HDAC2, MBD2, MBD3, and peripherally associated proteins CDK2AP1, CDK2AP2, GATAD2A, GATAD2B, CHD3, CHD4 and CHD5. The exact stoichiometry of the NuRD complex is unknown, and some subunits such as MBD2 and MBD3, GATAD2A and GATAD2B, and CHD3, CHD4 and CHD5 define mutually exclusive NuRD complexes. Component of a RCOR/GFI/KDM1A/HDAC complex. Component of a BHC histone deacetylase complex that contains HDAC1, HDAC2, HMG20B, KDM1A, RCOR1 and PHF21A. The BHC complex may also contain ZMYM2, ZNF217, ZMYM3, GSE1 and GTF2I. Part of a complex containing the core histones H2A, H2B, H3 and H4, DEK and unphosphorylated DAXX. Part of a complex containing ATR and CHD4. Forms a heterologous complex at least with YY1. Interacts in the late S-phase of DNA-replication with DNMT1 in the other transcriptional repressor complex composed of DNMT1, DMAP1, PCNA, CAF1. Component of a mSin3A corepressor complex that contains SIN3A, SAP130, SUDS3, ARID4B, HDAC1 and HDAC2. Part of a complex composed of TRIM28, HDAC1, HDAC2 and EHMT2. Part of a complex containing at least CDYL, MIER1, MIER2, HDAC1 and HDAC2. Component of a histone deacetylase complex containing DNTTIP1, ZNF541, HDAC1 and HDAC2. Forms a complex comprising APPL1, RUVBL2, APPL2, CTNNB1 and HDAC1. Interacts directly with GFI1. Interacts directly with GFI1B. Interacts with APEX1; the interaction is not dependent on the acetylated status of APEX1. Interacts with ATR. Interacts with BCL6 (non-acetylated form). Interacts with BEND3. Interacts with CBFA2T3. Interacts with CDK2AP1. Interacts with CHD4. Interacts with CHD5. Interacts with CHFR. Interacts with CRY1. Interacts with DNMT1. Interacts with GATAD2A. Interacts with HCFC1. Interacts with HDAC7. Interacts with HDAC10. Interacts with INSM1. Interacts with KDM4A. Interacts with MACROH2A1 (via the non-histone region). Interacts with MBD3L2. Interacts with MTA1, with a preference for sumoylated MTA1. Interacts with NACC2. Interacts with NRIP1. Interacts with PELP1. Interacts with PIMREG. Interacts with PRDM6. Interacts with PWWP2B. Interacts with SAP30. Interacts with SAP30L. Interacts with SETDB1. Interacts with SIX3. Interacts with SMARCAD1. Interacts with SNW1. Interacts with SPHK2. Interacts with SPEN/MINT. Interacts (CK2 phosphorylated form) with SP3. Interacts with SUV39H1. Interacts with TSHZ3 (via its N-terminus). Interacts with ZMYND8. Interacts with ZNF431. Interacts with ZNF263; recruited to the SIX3 promoter along with other proteins involved in chromatin modification and transcriptional corepression where it contributes to transcriptional repression. Identified in a complex with HDAC1, KCTD19, DNTTIP1 and ZNF541. Component of the SIN3B complex, which includes SIN3B, HDAC2, PHF12 and MORF4L1; interacts directly with all subunits.

Subcellular location. Nucleus. Cytoplasm.

Tissue specificity. Widely expressed; lower levels in brain and lung.

Post-translational modifications. S-nitrosylated by GAPDH. In neurons, S-nitrosylation at Cys-262 and Cys-274 does not affect enzyme activity, but induces HDAC2 release from chromatin. This in turn increases acetylation of histones surrounding neurotrophin-dependent gene promoters and promotes their transcription. In embryonic cortical neurons, S-Nitrosylation regulates dendritic growth and branching.

Activity regulation. Inositol tetraphosphate (1D-myo-inositol 1,4,5,6-tetrakisphosphate) may act as an intermolecular glue between HDAC2 and N-Cor repressor complex components.

Cofactor. Binds 2 Ca(2+) ions per subunit.

Similarity. Belongs to the histone deacetylase family. HD type 1 subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q92769-1	1	yes
Q92769-3	2

RefSeq proteins (1): NP_001518* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000286	HDACs	Family
IPR003084	HDAC_I/II	Family
IPR023696	Ureohydrolase_dom_sf	Homologous_superfamily
IPR023801	His_deacetylse_dom	Domain
IPR037138	His_deacetylse_dom_sf	Homologous_superfamily

Pfam: PF00850

Enzyme classification (BRENDA)

• EC 3.5.1.98 — histone deacetylase (BRENDA: 33 organisms, 161 substrates, 590 inhibitors, 88 Km, 32 kcat entries)

Substrate kinetics (BRENDA)

32 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
FLUOR DE LYS HDAC8 SUBSTRATE	0.14–1.1	9
AC-KHK(ACETYL)K(ACETYL)-7-AMIDO-4-METHYLCOUMARIN	0.273–2.403	6
FLUOR DE LYS HDAC SUBSTRATE	0.013–0.088	6
AC-FEK(ACETYL)-7-AMIDO-4-METHYLCOUMARIN	0.0023–0.0359	5
AC-GGK(ACETYL)-7-AMIDO-4-METHYLCOUMARIN	0.0043–0.0877	5
AC-GS(PO3)K(ACETYL)-7-AMIDO-4-METHYLCOUMARIN	0.0123–0.0666	5
AC-GSK(ACETYL)-7-AMIDO-4-METHYLCOUMARIN	0.004–0.0241	5
AC-IHK(ACETYL)-7-AMIDO-4-METHYLCOUMARIN	0.0007–0.108	5
AC-KYK(ACETYL)-7-AMIDO-4-METHYLCOUMARIN	0.0044–0.107	4
FLUOR DE LYS	—	4
AC-LYK(ACETYL)-7-AMIDO-4-METHYLCOUMARIN	0.0069–0.03	3
AC-VLK(ACETYL)-7-AMIDO-4-METHYLCOUMARIN	0.0119–0.0221	3
RHK(ACETYL)K(ACETYL)-FLUOROPHORE	0.16–1.1	3
AC-DQK(ACETYL)-7-AMIDO-4-METHYLCOUMARIN	0.0024–0.0165	2
BENZYLOXYCARBONYL-L-LYS(ACETYL)-7-AMIDO-4-METHYL	0.078–0.099	2

Catalyzed reactions (Rhea)

• N(6)-acetyl-L-lysyl-[protein] + H2O = L-lysyl-[protein] + acetate (RHEA:58108)
• N(6)-acetyl-L-lysyl-[histone] + H2O = L-lysyl-[histone] + acetate (RHEA:58196)
• N(6)-(2E)-butenoyl-L-lysyl-[protein] + H2O = (2E)-2-butenoate + L-lysyl-[protein] (RHEA:69172)
• N(6)-(2-hydroxyisobutanoyl)-L-lysyl-[protein] + H2O = 2-hydroxy-2-methylpropanoate + L-lysyl-[protein] (RHEA:69176)
• N(6)-[(S)-lactoyl]-L-lysyl-[protein] + H2O = (S)-lactate + L-lysyl-[protein] (RHEA:81387)

UniProt features (89 total): helix 23, binding site 15, strand 15, modified residue 8, cross-link 7, turn 6, sequence conflict 5, compositionally biased region 3, region of interest 2, sequence variant 2, chain 1, splice variant 1, active site 1

Structure

Experimental structures (PDB)

showing 30 of 48 structures by resolution:

PDB	Title	Method	Resolution (Å)
7KBG	Structure of Human HDAC2 in complex with a 2-substituted benzamide inhibitor (compound 20)	X-RAY DIFFRACTION	1.26
6WBZ	Structure of Human HDAC2 in complex with an ethyl ketone inhibitor containing a …	X-RAY DIFFRACTION	1.32
6WBW	Structure of Human HDAC2 in complex with an ethyl ketone inhibitor	X-RAY DIFFRACTION	1.46
7LTL	STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH AN INHIBITOR LACKING A ZINC BINDING GROUP …	X-RAY DIFFRACTION	1.49
6XEB	STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH KETONE INHIBITOR (COMPOUND E)	X-RAY DIFFRACTION	1.5
7ZZP	Structure of HDAC2 complexed with an inhibitory ligand	X-RAY DIFFRACTION	1.52
6WHN	Histone deacetylases complex with peptide macrocycles	X-RAY DIFFRACTION	1.54
7MOT	Structure of HDAC2 in complex with an inhibitor (compound 9)	X-RAY DIFFRACTION	1.54
7MOZ	Structure of HDAC2 in complex with a macrocyclic inhibitor (compound 25)	X-RAY DIFFRACTION	1.54
6XDM	STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH AN ARYL KETONE INHIBITOR	X-RAY DIFFRACTION	1.56
7ZZT	Ligand binding to HDAC2	X-RAY DIFFRACTION	1.56
4LY1	Structure of Human HDAC2 in complex with inhibitor …	X-RAY DIFFRACTION	1.57
7LTK	STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH AN INHIBITOR THAT LACKS A ZINC BINDING GROUP …	X-RAY DIFFRACTION	1.59
9K0G	Structure of Human HDAC2 in complex with inhibitor …	X-RAY DIFFRACTION	1.62
7JS8	STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH AN ETHYL KETONE INHIBITOR CONTAINING A …	X-RAY DIFFRACTION	1.63
5IWG	HDAC2 WITH LIGAND BRD4884	X-RAY DIFFRACTION	1.66
7MOX	Structure of HDAC2 in complex with an inhibitor (compound 14)	X-RAY DIFFRACTION	1.69
6XEC	STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH KETONE INHIBITOR (COMPOUND O)	X-RAY DIFFRACTION	1.7
7MOS	Structure of HDAC2 in complex with a macrocyclic inhibitor (compound 4)	X-RAY DIFFRACTION	1.7
5IX0	HDAC2 WITH LIGAND BRD7232	X-RAY DIFFRACTION	1.72
7ZZW	Ligand binding to HDAC2	X-RAY DIFFRACTION	1.73
8A0B	Inhibitor binding to HDAC2	X-RAY DIFFRACTION	1.75
7MOY	Structure of HDAC2 in complex with an inhibitor (compound 19)	X-RAY DIFFRACTION	1.78
9JWJ	Structure of Human HDAC2 in complex with inhibitor …	X-RAY DIFFRACTION	1.78
7LTG	STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH APICIDIN	X-RAY DIFFRACTION	1.8
9NTB	Crystal structure of human HDAC2 in complex with TNG260	X-RAY DIFFRACTION	1.8
4LXZ	Structure of Human HDAC2 in complex with SAHA (vorinostat)	X-RAY DIFFRACTION	1.85
7ZZU	Inhibitory Ligand binding to HDAC2	X-RAY DIFFRACTION	1.85
7ZZS	HDAC2 complexed with an inhibitory ligand	X-RAY DIFFRACTION	1.88
7ZZO	HDAC2 in complex with an inhibitor	X-RAY DIFFRACTION	2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q92769-F1	86.01	0.76

Human Protein Atlas

Protein class: Enzymes, ENZYME proteins, Hydrolases, Predicted intracellular proteins, Plasma proteins, Cancer-related genes, Candidate cancer biomarkers, FDA approved drug targets, Small molecule drugs

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): nucleoplasm

Antibody reliability (HPA): IH supported · IF supported

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1)

Position	Role
142

Ligand- & substrate-binding residues (15)

Position	Role
177	Ca(2+)
177	Zn(2+)
179	Ca(2+)
179	Zn(2+)
188	Ca(2+)
191	Ca(2+)
194	Ca(2+)
198	Ca(2+)
199	Ca(2+)
223	Ca(2+)
265	Zn(2+)
271	1D-myo-inositol 1,4,5,6-tetrakisphosphate
28	1D-myo-inositol 1,4,5,6-tetrakisphosphate
32	1D-myo-inositol 1,4,5,6-tetrakisphosphate
175	Ca(2+)

Post-translational modifications (15)

Type	Positions
N6-acetyllysine	75, 221
S-nitrosocysteine	262, 274
Phosphoserine	394, 407, 422, 424
Glycyl lysine isopeptide (lys-gly) (interchain with g-cter in sumo2)	75, 439, 452, 458, 462, 478, 481

Function

Pathways and Gene Ontology

Reactome pathways

14 curated (TAS) of 76; 11 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

showing 60 of 76 pathways:

ID	Pathway	Evidence
R-HSA-2894862	Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants ⚕	curated
R-HSA-2644606	Constitutive Signaling by NOTCH1 PEST Domain Mutants ⚕	curated
R-HSA-9679191	Potential therapeutics for SARS ⚕	curated
R-HSA-983231	Factors involved in megakaryocyte development and platelet production	curated
R-HSA-3214815	HDACs deacetylate histones	curated
R-HSA-9940951	Interaction of NuRD complexes with transcription factors	curated
R-HSA-9764725	Negative Regulation of CDH1 Gene Transcription	curated
R-HSA-350054	Notch-HLH transcription pathway	curated
R-HSA-9937850	NuRD complex assembly	curated
R-HSA-73762	RNA Polymerase I Transcription Initiation	curated
R-HSA-9022692	Regulation of MECP2 expression and activity	curated
R-HSA-6804758	Regulation of TP53 Activity through Acetylation	curated
R-HSA-9701898	STAT3 nuclear events downstream of ALK signaling	curated
R-HSA-4551638	SUMOylation of chromatin organization proteins	curated
R-HSA-1643685	Disease ⚕	—
R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers ⚕	—
R-HSA-5663205	Infectious disease ⚕	—
R-HSA-9679506	SARS-CoV Infections ⚕	—
R-HSA-2894858	Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer ⚕	—
R-HSA-2644602	Signaling by NOTCH1 PEST Domain Mutants in Cancer ⚕	—
R-HSA-2644603	Signaling by NOTCH1 in Cancer ⚕	—
R-HSA-9824446	Viral Infection Pathways ⚕	—
R-HSA-418990	Adherens junctions interactions	—
R-HSA-9843745	Adipogenesis	—
R-HSA-446728	Cell junction organization	—
R-HSA-1500931	Cell-Cell communication	—
R-HSA-421270	Cell-cell junction organization	—
R-HSA-3247509	Chromatin modifying enzymes	—
R-HSA-4839726	Chromatin organization	—
R-HSA-73887	Death Receptor Signaling	—
R-HSA-1266738	Developmental Biology	—
R-HSA-9976102	Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)	electronic
R-HSA-9619665	EGR2 and SOX10-mediated initiation of Schwann cell myelination	electronic
R-HSA-427389	ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression	electronic
R-HSA-212165	Epigenetic regulation of gene expression	—
R-HSA-9614085	FOXO-mediated transcription	—
R-HSA-9615017	FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	electronic
R-HSA-74160	Gene expression (Transcription)	—
R-HSA-212436	Generic Transcription Pathway	—
R-HSA-109582	Hemostasis	—
R-HSA-9006925	Intracellular signaling by second messengers	—
R-HSA-9022699	MECP2 regulates neuronal receptors and channels	electronic
R-HSA-392499	Metabolism of proteins	—
R-HSA-2122947	NOTCH1 Intracellular Domain Regulates Transcription	electronic
R-HSA-5250941	Negative epigenetic regulation of rRNA expression	—
R-HSA-9675108	Nervous system development	—
R-HSA-427413	NoRC negatively regulates rRNA expression	electronic
R-HSA-1257604	PIP3 activates AKT signaling	—
R-HSA-6807070	PTEN Regulation	—
R-HSA-5250913	Positive epigenetic regulation of rRNA expression	—
R-HSA-597592	Post-translational protein modification	—
R-HSA-73854		—
R-HSA-73864	RNA Polymerase I Transcription	—
R-HSA-73857	RNA Polymerase II Transcription	—
R-HSA-9764265	Regulation of CDH1 Expression and Function	—
R-HSA-9764560	Regulation of CDH1 Gene Transcription	—
R-HSA-9764274	Regulation of Expression and Function of Type I Classical Cadherins	—
R-HSA-9759476	Regulation of Homotypic Cell-Cell Adhesion	—
R-HSA-8943724	Regulation of PTEN gene transcription	electronic
R-HSA-5633007	Regulation of TP53 Activity	—

MSigDB gene sets: 601 (showing top): GOBP_CIRCADIAN_RHYTHM, MORF_MTA1, GOBP_DENDRITE_DEVELOPMENT, PID_HDAC_CLASSI_PATHWAY, MORF_DNMT1, GOBP_NEGATIVE_REGULATION_OF_DENDRITIC_SPINE_DEVELOPMENT, REACTOME_SIGNALING_BY_NOTCH, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_RESPONSE_TO_ETHANOL, GOBP_POSITIVE_REGULATION_OF_REPRODUCTIVE_PROCESS, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_BEHAVIOR, PID_TELOMERASE_PATHWAY, GOBP_RESPONSE_TO_COCAINE

GO Biological Process (52): negative regulation of transcription by RNA polymerase II (GO:0000122), response to amphetamine (GO:0001975), cardiac muscle hypertrophy (GO:0003300), chromatin remodeling (GO:0006338), DNA-templated transcription (GO:0006351), positive regulation of cell population proliferation (GO:0008284), response to xenobiotic stimulus (GO:0009410), epidermal cell differentiation (GO:0009913), positive regulation of epithelial to mesenchymal transition (GO:0010718), negative regulation of neuron projection development (GO:0010977), dendrite development (GO:0016358), negative regulation of cell migration (GO:0030336), negative regulation of transforming growth factor beta receptor signaling pathway (GO:0030512), response to caffeine (GO:0031000), heterochromatin formation (GO:0031507), response to lipopolysaccharide (GO:0032496), positive regulation of interleukin-1 production (GO:0032732), positive regulation of tumor necrosis factor production (GO:0032760), circadian regulation of gene expression (GO:0032922), positive regulation of intracellular estrogen receptor signaling pathway (GO:0033148), cellular response to heat (GO:0034605), response to nicotine (GO:0035094), response to cocaine (GO:0042220), odontogenesis of dentin-containing tooth (GO:0042475), regulation of cell fate specification (GO:0042659), embryonic digit morphogenesis (GO:0042733), negative regulation of apoptotic process (GO:0043066), positive regulation of proteolysis (GO:0045862), negative regulation of DNA-templated transcription (GO:0045892), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of transcription by RNA polymerase II (GO:0045944), regulation of embryonic development (GO:0045995), behavioral response to ethanol (GO:0048149), positive regulation of oligodendrocyte differentiation (GO:0048714), progesterone receptor signaling pathway (GO:0050847), response to hyperoxia (GO:0055093), hair follicle placode formation (GO:0060789), negative regulation of dendritic spine development (GO:0061000), eyelid development in camera-type eye (GO:0061029), fungiform papilla formation (GO:0061198), cellular response to hydrogen peroxide (GO:0070301), cellular response to retinoic acid (GO:0071300), cellular response to transforming growth factor beta stimulus (GO:0071560), positive regulation of male mating behavior (GO:1902437), negative regulation of stem cell population maintenance (GO:1902455), positive regulation of stem cell population maintenance (GO:1902459), cellular response to dopamine (GO:1903351), response to amyloid-beta (GO:1904645), regulation of stem cell differentiation (GO:2000736), chromatin organization (GO:0006325), rhythmic process (GO:0048511), response to alcohol (GO:0097305)

GO Molecular Function (23): transcription coregulator binding (GO:0001221), chromatin binding (GO:0003682), RNA binding (GO:0003723), histone deacetylase activity (GO:0004407), enzyme binding (GO:0019899), heat shock protein binding (GO:0031072), protein lysine deacetylase activity (GO:0033558), histone binding (GO:0042393), histone deacetylase binding (GO:0042826), NF-kappaB binding (GO:0051059), RNA polymerase II-specific DNA-binding transcription factor binding (GO:0061629), histone deacetylase activity, hydrolytic mechanism (GO:0141221), histone decrotonylase activity (GO:0160009), protein de-2-hydroxyisobutyrylase activity (GO:0160010), protein lysine delactylase activity (GO:0160216), promoter-specific chromatin binding (GO:1990841), protein binding (GO:0005515), hydrolase activity (GO:0016787), hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides (GO:0016811), deacetylase activity (GO:0019213), nucleosomal DNA binding (GO:0031492), DNA-binding transcription factor binding (GO:0140297), protein decrotonylase activity (GO:0160008)

GO Cellular Component (10): histone deacetylase complex (GO:0000118), chromosome, telomeric region (GO:0000781), chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), NuRD complex (GO:0016581), protein-containing complex (GO:0032991), ESC/E(Z) complex (GO:0035098), Sin3-type complex (GO:0070822)

Reactome top-level categories

19 top-level categories:

Category	Pathways
Transcriptional Regulation by MECP2	2
p75 NTR receptor-mediated signalling	1
Signaling by NOTCH1	1
Signaling by NOTCH1 PEST Domain Mutants in Cancer	1
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer	1
Chromatin modifying enzymes	1
Generic Transcription Pathway	1
Positive epigenetic regulation of rRNA expression	1
Negative epigenetic regulation of rRNA expression	1
SUMO E3 ligases SUMOylate target proteins	1
Regulation of TP53 Activity	1
RNA Polymerase I Transcription	1
PTEN Regulation	1
FOXO-mediated transcription	1
Nervous system development	1
SARS-CoV Infections	1
Signaling by ALK	1
Regulation of CDH1 Gene Transcription	1
Hemostasis	1

GO top-level categories

showing 60 of 83 GO namespaces:

Category	Terms
protein binding	3
cellular anatomical structure	3
neuron projection development	2
binding	2
histone modifying activity	2
catalytic activity, acting on a protein	2
hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides	2
deacylase activity	2
histone deacetylase complex	2
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
response to amine	1
striated muscle hypertrophy	1
chromatin organization	1
gene expression	1
RNA biosynthetic process	1
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
response to chemical	1
epidermis development	1
epithelial cell differentiation	1
epithelial to mesenchymal transition	1
regulation of epithelial to mesenchymal transition	1
positive regulation of cell differentiation	1
positive regulation of multicellular organismal process	1
regulation of neuron projection development	1
negative regulation of cell projection organization	1
anatomical structure development	1
cell migration	1
regulation of cell migration	1
negative regulation of cell motility	1
transforming growth factor beta receptor signaling pathway	1
regulation of transforming growth factor beta receptor signaling pathway	1
negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	1
response to purine-containing compound	1
response to alkaloid	1
cellular component assembly	1
heterochromatin boundary formation	1
negative regulation of gene expression, epigenetic	1
heterochromatin organization	1
response to molecule of bacterial origin	1
response to lipid	1
response to oxygen-containing compound	1
positive regulation of cytokine production	1
interleukin-1 production	1
regulation of interleukin-1 production	1
tumor necrosis factor production	1
regulation of tumor necrosis factor production	1
positive regulation of tumor necrosis factor superfamily cytokine production	1
circadian rhythm	1
regulation of gene expression	1
estrogen receptor signaling pathway	1
positive regulation of intracellular steroid hormone receptor signaling pathway	1
regulation of intracellular estrogen receptor signaling pathway	1
transcription factor binding	1
nucleic acid binding	1
protein lysine deacetylase activity	1
deacetylase activity	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 30 of 86 annotations. The rest are phylogenetic / computational / electronic (IEA).

30 experimentally-supported GO terms:

GO term	NS	Evidence
chromatin remodeling	BP	direct assay
heterochromatin formation	BP	mutant phenotype
negative regulation of transcription by RNA polymerase II	BP	mutant phenotype
positive regulation of cell population proliferation	BP	mutant phenotype
positive regulation of intracellular estrogen receptor signaling pathway	BP	mutant phenotype
positive regulation of proteolysis	BP	mutant phenotype
positive regulation of transcription by RNA polymerase II	BP	mutant phenotype
progesterone receptor signaling pathway	BP	mutant phenotype
ESC/E(Z) complex	CC	direct assay
NuRD complex	CC	direct assay
Sin3-type complex	CC	direct assay
chromatin	CC	high-throughput assay
chromosome, telomeric region	CC	direct assay
cytoplasm	CC	direct assay
histone deacetylase complex	CC	direct assay
nucleoplasm	CC	direct assay
nucleus	CC	direct assay
protein-containing complex	CC	direct assay
NF-kappaB binding	MF	physical interaction
RNA binding	MF	high-throughput assay
RNA polymerase II-specific DNA-binding transcription factor binding	MF	physical interaction
enzyme binding	MF	physical interaction
histone binding	MF	direct assay
histone deacetylase activity	MF	direct assay
histone deacetylase binding	MF	physical interaction
histone decrotonylase activity	MF	direct assay
protein de-2-hydroxyisobutyrylase activity	MF	direct assay
protein lysine deacetylase activity	MF	mutant phenotype
protein lysine delactylase activity	MF	direct assay
transcription coregulator binding	MF	physical interaction

Protein interactions and networks

STRING

showing 15 of 4,548 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HDAC2	SAP30	O75446	937
HDAC2	RCOR1	Q9UKL0	879
HDAC2	RBBP4	P31149	853
HDAC2	SIN3A	Q96ST3	851
HDAC2	HDAC1	Q13547	850
HDAC2	H3C14	Q71DI3	844
HDAC2	H3-5	Q6NXT2	844
HDAC2	H3-4	Q16695	844
HDAC2	H3-7	Q5TEC6	844
HDAC2	H3-3A	P06351	843
HDAC2	H3C1	P02295	843
HDAC2	KDM1A	O60341	839
HDAC2	RBBP7	Q16576	832
HDAC2	SIRT1	Q96EB6	831
HDAC2	SUDS3	Q9H7L9	819

IntAct

Human interaction partners of HDAC2 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

showing 30 of 53 partners by confidence:

Partner	Interaction type	MIscore	Records
HDAC1	physical association	0.950	5
KDM1A	association	0.890	3
MTA1	physical association	0.890	1
SIN3A	physical association	0.880	2
BRMS1	physical association	0.720	2
BCL11B	physical association	0.700	2
ZNF516	physical association	0.660	2
SIN3B	association	0.640	1
SRA1	physical association	0.590	2
CSNK2A1	phosphorylation reaction	0.590	1
K8	colocalization	0.540	5
C22orf31	association	0.530	1
SUV39H1	physical association	0.520	3
MBD1	physical association	0.520	2
DAXX	physical association	0.520	1
SNAI1	deacetylation reaction	0.520	1
RFX5	physical association	0.500	2
TXNIP	physical association	0.500	2
HCFC1	physical association	0.500	1
ZNF827	physical association	0.500	1
DBP	colocalization	0.430	1
E7	physical association	0.400	2
NPM1	physical association	0.400	2
BUB1B	physical association	0.400	1
COL14A1	physical association	0.400	1
ESPL1	physical association	0.400	1
HDAC10	physical association	0.400	1
KIF4B	physical association	0.400	1
MIR1253	physical association	0.400	1
MIR147B	physical association	0.400	1

BioGRID (1,782 interactions; top human partners by supporting records in a sample of 600 records): HDAC1 (Affinity Capture-Western; 13 records), KDM1A (Co-fractionation; 7 records), SIN3A (Co-fractionation; 7 records), HMG20B (Affinity Capture-MS; 6 records), GTF2I (Affinity Capture-MS; 5 records), MTA1 (Co-fractionation; 5 records), MTA2 (Co-fractionation; 5 records), RBBP7 (Affinity Capture-MS; 5 records), CHD4 (Co-fractionation; 4 records), CUL4B (Affinity Capture-Western; 4 records), FOXK2 (Affinity Capture-MS; 4 records), GATAD2B (Affinity Capture-MS; 4 records), PHF21A (Co-purification; 4 records), RBBP4 (Co-fractionation; 4 records), USP4 (Affinity Capture-Western; 4 records)

SIGNOR signaling

showing 38 of 51 signaling interactions:

A	Effect	B	Mechanism
CCND1	up-regulates	HDAC2	binding
HDAC2	up-regulates	CCND1	binding
CSNK2A1	up-regulates	HDAC2	phosphorylation
N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide	down-regulates	HDAC2	“chemical inhibition”
3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide	down-regulates	HDAC2	“chemical inhibition”
HDAC2	“form complex”	“CoREST-HDAC complex”	binding
CSNK2A1	“up-regulates activity”	HDAC2	phosphorylation
CSNK2A2	“up-regulates activity”	HDAC2	phosphorylation
HDAC2	“down-regulates quantity by repression”	TWIST1	“transcriptional regulation”
HDAC2	“down-regulates quantity by repression”	SNAI2	“transcriptional regulation”
HDAC2	“down-regulates quantity by repression”	CIITA	deacetylation
“valproic acid”	“down-regulates activity”	HDAC2	“chemical inhibition”
JWOGUUIOCYMBPV-GMFLJSBRSA-N	“down-regulates activity”	HDAC2	“chemical inhibition”
HDAC2	“up-regulates activity”	ZNF318	binding
(S)-N-Hydroxy-4-(3-methyl-2-phenylbutanamido)benzamide	“down-regulates activity”	HDAC2	“chemical inhibition”
HDAC2	“form complex”	“MBD2/NuRD complex”	binding
HDAC2	“form complex”	“MBD3/NuRD complex”	binding
HDAC2	“form complex”	“BHC complex”	binding
HDAC2	“form complex”	“MECP2/SIN3A/HDAC complex”	binding
HDAC2	down-regulates	Epigenetic_regulation
PPP2CA	“down-regulates activity”	HDAC2	dephosphorylation
PBK	“up-regulates activity”	HDAC2	phosphorylation
NOS1	“down-regulates activity”	HDAC2	s-nitrosylation
HDAC2	“down-regulates quantity by repression”	HPGD	“transcriptional regulation”
ABL1	“up-regulates quantity by stabilization”	HDAC2	phosphorylation
belinostat	“down-regulates activity”	HDAC2	“chemical inhibition”
panobinostat	“down-regulates activity”	HDAC2	“chemical inhibition”
entinostat	“down-regulates activity”	HDAC2	“chemical inhibition”
“N-[4-[(hydroxyamino)-oxomethyl]phenyl]carbamic acid [6-(diethylaminomethyl)-2-naphthalenyl]methyl ester”	“down-regulates activity”	HDAC2	“chemical inhibition”
vorinostat	“down-regulates activity”	HDAC2	“chemical inhibition”
N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide	“down-regulates activity”	HDAC2	“chemical inhibition”
N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide	“down-regulates activity”	HDAC2	“chemical inhibition”
“trichostatin A”	“down-regulates activity”	HDAC2	“chemical inhibition”
romidepsin	“down-regulates activity”	HDAC2	“chemical inhibition”
6-(1,3-dioxo-2-benzo[de]isoquinolinyl)-N-hydroxyhexanamide	“down-regulates activity”	HDAC2	“chemical inhibition”
tacedinaline	“down-regulates activity”	HDAC2	“chemical inhibition”
CUDC-101	“down-regulates activity”	HDAC2	“chemical inhibition”
HDAC2	“down-regulates activity”	YY1	deacetylation

Protein complexes (CORUM) (62)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

showing 60 of 62 complexes by size:

Complex	Subunits	Members
★ ALL-1 supercomplex	28	MTA2, SIN3A, SMARCC2, TAF12, TBP, WDR5, EFTUD2, RBBP7, SAP18, SYMPK, TAF9, HDAC1, KMT2A, MBD3, RBBP5, SAP30, SMARCA2, TAF1, TAF6, CPSF2, HDAC2, KDM1A, RAN, RBBP4, SMARCA5, SMARCB1, SMARCC1, CHD3
★ LARC complex (LCR-associated remodeling complex)	19	SMARCC1, SMARCC2, SMARCD2, SMARCE1, ACTL6A, CHD4, MBD3, RBBP4, ACTB, MTA2, SMARCA4, HDAC1, HDAC2, HNRNPC, MBD2, ARID1A, DPF2, GATAD2B, SMARCB1
★ HCF-1 complex	18	HSPA8, RBBP7, SAP30, SETD1A, SIN3A, HCFC1, OGT, SP1, WDR5, HDAC1, SIN3B, SUDS3, ASH2L, HSP90AA1, RBBP4, HDAC2, HSPA4, HSPA5
★ Anti-HDAC2 complex	17	CHD3, CHD4, GTF2I, HDAC2, HMG20B, PHF21A, RBBP4, ZMYM2, ZMYM3, GSE1, HDAC1, MTA1, MTA2, RCOR1, SIN3A, KDM1A, RBBP7
★ CtBP complex	17	ZEB1, CBX4, CDYL, CTBP1, HDAC1, HDAC2, RCOR1, ZEB2, EHMT2, KDM1A, RCOR3, RREB1, ZNF516, CTBP2, LCOR, EHMT1, ZNF217
★ SNF2h-cohesin-NuRD complex	16	MBD2, MTA2, RBBP7, SMARCA5, MTA1, RBBP4, HDAC2, RAD21, SMC3, STAG1, STAG2, BAZ1A, HDAC1, MBD3, SMC1A, CHD3
★ SIN3-ING1b complex II	16	ARID1A, ING1, RBBP7, ACTL6A, ARID4B, RBBP4, SAP18, SAP30, SMARCA4, SMARCC1, HDAC1, HDAC2, SMARCD1, SIN3A, SMARCB1, SMARCC2
★ BRM-SIN3A complex	15	RBBP4, SMARCA2, SMARCB1, SMARCC2, SMARCD1, ACTL6A, HDAC1, HDAC2, PRMT5, SIN3A, SMARCD3, ARID1A, SMARCC1, SMARCD2, SMARCE1
★ BRG1-SIN3A complex	14	SMARCD1, SMARCD2, SMARCD3, ARID1A, RBBP4, SIN3A, SMARCA4, SMARCB1, SMARCE1, ACTL6A, HDAC2, PRMT5, SMARCC1, SMARCC2
★ ING2 complex	13	BRMS1L, SAP30, SIN3A, SUDS3, ARID4A, BRMS1, HDAC1, HDAC2, ING2, RBBP4, RBBP7, SAP130, ARID4B
★ MBD3-NuRD complex	13	HDAC2, MBD3, RBBP4, ZNF598, CDK2AP1, CHD3, CHD4, GATAD2B, HDAC1, MTA2, RBBP7, ZMYND8, GATAD2A
★ PRC1.6a complex	13	RYBP, TFDP1, HDAC1, MAX, MGA, PCGF6, WDR5, CBX3, E2F6, HDAC2, L3MBTL2, RING1, RNF2
★ PRC1.6b complex	13	CBX3, HDAC1, L3MBTL2, MGA, PCGF6, RING1, WDR5, E2F6, HDAC2, MAX, RNF2, TFDP1, YAF2
★ BRM-SIN3A-HDAC complex	12	SMARCE1, ACTL6A, PRMT5, SMARCC2, SMARCD1, ARID1A, HDAC2, SIN3A, SMARCA2, SMARCB1, SMARCC1, SMARCD2
★ anti-BHC110 complex	11	GSE1, HDAC2, ZMYM2, ZMYM3, ZNF217, GTF2I, HDAC1, HMG20B, KDM1A, PHF21A, RCOR1
★ SIN3-SAP25 complex	11	HDAC2, RBBP4, SAP30, SIN3A, SUDS3, RBBP7, SAP130, SAP18, SAP25, ARID4B, HDAC1
★ BRG1-SIN3A-HDAC containing SWI/SNF remodeling complex I	11	SMARCE1, ACTL6A, PRMT5, SIN3A, SMARCA4, SMARCC2, ARID1A, HDAC2, SMARCB1, SMARCC1, SMARCD1
★ BHC110 complex	10	ZNF217, GSE1, HDAC1, KDM1A, PHF21A, RCOR1, ZMYM2, ZNF516, HDAC2, HMG20B
★ mSin3A corepressor complex	9	ARID4B, HDAC2, RBBP4, RBBP7, SAP130, SUDS3, HDAC1, SAP30, SIN3A
★ CtBP core complex	9	EHMT2, HDAC1, HDAC2, RCOR1, ZEB1, CTBP1, EHMT1, KDM1A, CTBP2
★ MeCP1 complex	9	MTA2, RBBP4, RBBP7, MBD3, CHD4, GATAD2B, HDAC1, HDAC2, MBD2
★ SIN3-ING1b complex I	9	SAP18, SAP30, ARID4B, HDAC1, RBBP4, SIN3A, HDAC2, ING1, RBBP7
★ CDYL-complex	9	HDAC1, MIER1, REST, WIZ, CDYL, EHMT1, EHMT2, HDAC2, SETDB1
★ SIX3-LSD1-NuRD(MTA3) complex	9	HDAC1, HDAC2, KDM1A, MBD2, RBBP7, MBD3, MTA3, RBBP4, SIX3
★ SAP complex (Sin3-associated protein complex)	8	SAP30, SIN3A, ARID4B, HDAC1, HDAC2, RBBP4, RBBP7, SAP130
★ MeCP1 complex	8	RBBP7, CHD4, HDAC1, HDAC2, MBD2, MBD3, MTA2, RBBP4
★ BRMS1-mSin3A corepressor complex	8	SAP30, SIN3A, SIN3B, BRMS1, HDAC1, HDAC2, RBBP4, RBBP7
★ MTA2 complex	8	MBD3, MTA2, RBBP4, RBBP7, SIN3A, CHD4, HDAC1, HDAC2
★ NCOR2 complex	7	NCOR2, SAP30, SIN3A, HDAC1, HDAC2, HDAC3, NCOR1
★ SIN3 complex	7	SAP30, SIN3A, HDAC1, HDAC2, RBBP4, RBBP7, SAP18
★ NuRD.1 complex	7	CHD4, HDAC1, HDAC2, MBD3, MTA1, RBBP4, RBBP7
★ Mi2/NuRD complex	7	MBD3, MTA2, RBBP4, RBBP7, CHD4, HDAC1, HDAC2
★ NRD complex (Nucleosome remodeling and deacetylation complex)	7	HDAC2, KDM1A, MTA1, RBBP4, CHD3, CHD4, HDAC1
★ CoREST-HDAC complex	7	HMG20B, KDM1A, PHF21A, RCOR1, ZNF217, HDAC1, HDAC2
★ HDAC2-asscociated core complex	7	RBBP7, CHD3, GATAD2A, HDAC2, MBD3, MTA2, RBBP4
★ SIN3-HDAC-SAP30-ARID4 complex	7	RBBP4, RBBP7, SAP30, SIN3A, ARID4B, HDAC1, HDAC2
★ BRAF35-BRCA2 complex	7	KDM1A, PHF21A, RCOR1, BRCA2, HDAC1, HDAC2, HMG20B
★ CDK7-CCNH-ESR1-HDAC2-MNAT1-MTA1 complex	6	CCNH, CDK7, ESR1, HDAC2, MNAT1, MTA1
★ NCOR-SIN3-HDAC-HESX1 complex	6	HESX1, NCOR2, SIN3A, SIN3B, HDAC1, HDAC2
★ BHC complex	6	HMG20B, KDM1A, PHF21A, RCOR1, HDAC1, HDAC2
★ MTA1 complex	6	HDAC1, HDAC2, MBD3, MTA1, RBBP4, RBBP7
★ mSin3A corepressor complex	5	RBBP7, SIN3A, HDAC1, HDAC2, RBBP4
★ XFIM complex	5	GTF2I, HDAC1, HDAC2, KDM1A, ZMYM3
★ CDH4-HDAC2-MTA2-RBBP7-TWIST1 complex	5	CHD4, HDAC2, MTA2, RBBP7, TWIST1
★ MTA1-HDAC core complex	5	HDAC1, HDAC2, MTA1, RBBP4, RBBP7
★ MiDAC complex	4	DNTTIP1, HDAC1, HDAC2, MIDEAS
★ DNTTIP1-ZNF541-HDAC1-HDAC2 complex	4	DNTTIP1, HDAC1, HDAC2, ZNF541
★ NCOR-SIN3-RPD3 complex	4	SIN3A, SIN3B, HDAC2, NCOR2
★ MeCP2-SIN3A-HDAC complex	4	SIN3A, HDAC1, HDAC2, MECP2
★ HDAC1-HDAC2-MIER1-MIER2 complex	4	HDAC2, MIER1, MIER2, HDAC1
★ E2F1-HDAC2-PA2G4-RB1 complex	4	E2F1, HDAC2, PA2G4, RB1
★ ATR-HDAC2-CHD4 complex	3	ATR, CHD4, HDAC2
★ BRCA1-HDAC1-HDAC2 complex	3	BRCA1, HDAC1, HDAC2
★ mSin3A-HDAC1-HDAC2 complex	3	HDAC1, HDAC2, SIN3A
★ MAD1-mSin3A-HDAC2 complex	3	HDAC2, MXD1, SIN3A
★ AJUBA-GFI1-HDAC2 complex	3	AJUBA, GFI1, HDAC2
★ HDAC2-MYCN-SP1 complex	3	MYCN, SP1, HDAC2
★ ATR-HDAC2 complex	2	ATR, HDAC2
★ CoREST-HDAC2 complex	2	HDAC2, RCOR1
★ SNF2h-HDAC12 complex	2	HDAC2, SMARCA5

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 53 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
HDACs deacetylate histones	5	15.4×	1e-03
Regulation of PD-L1(CD274) transcription	5	13.9×	2e-03
Chromatin organization	5	10.5×	3e-03
Chromatin modifying enzymes	5	9.3×	4e-03

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of miRNA transcription	5	33.8×	4e-05
chromatin remodeling	9	15.3×	9e-07
negative regulation of cell migration	5	13.0×	2e-03
chromatin organization	5	11.5×	2e-03
negative regulation of gene expression	7	11.2×	2e-04
positive regulation of gene expression	10	9.0×	1e-05
transcription by RNA polymerase II	5	8.2×	8e-03
negative regulation of apoptotic process	9	7.3×	2e-04

Disease & clinical

Genetic variants

Variant evidence for HDAC2: 63 ClinVar records (0 pathogenic / likely pathogenic); 3 GWAS associations.

ClinVar

63 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	31
Likely benign	5
Benign	3

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 29 predictions of 1,284):

Position(s)	Effect	Δscore	Sites
6:113941706–113941707	donor_loss	1.0000	6
6:113941766–113941767	acceptor_loss	1.0000	6
6:113943349–113943350	donor_loss	1.0000	5
6:113943380	donor_gain	1.0000
6:113943507–113943508	acceptor_loss	1.0000	4
6:113943513	acceptor_gain	1.0000
6:113943516–113943518	acceptor_gain	1.0000	2
6:113943521	acceptor_gain	1.0000
6:113944274	donor_gain	1.0000
6:113944278–113944279	donor_loss	1.0000	2

AlphaMissense

2,186 missense substitutions predicted likely pathogenic (of 3,233 scored), across 413 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M31	9	0.986	1.000
M38	9	0.948	1.000
M351	9	0.919	0.987
M195	9	0.907	0.999
H142	8	1.000	1.000
D177	8	1.000	1.000
H179	8	1.000	1.000
D265	8	1.000	1.000
D270	8	1.000	1.000
H29	8	0.999	1.000
D100	8	0.999	1.000
H141	8	0.999	1.000
D156	8	0.999	1.000
D175	8	0.999	1.000
H180	8	0.999	1.000
D182	8	0.999	1.000
H200	8	0.999	1.000
H69	8	0.998	0.999
F104	8	0.998	1.000
F151	8	0.998	1.000

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

5 prognostic cancer types:

Cancer	Prognostic	p-value
Liver Hepatocellular Carcinoma (TCGA)	unfavorable	1.81e-11
Kidney Renal Clear Cell Carcinoma (TCGA)	favorable	9.82e-06
Kidney Chromophobe (TCGA)	unfavorable	2.4e-05
Liver Hepatocellular Carcinoma (validation)	unfavorable	7.88e-05
Breast Invasive Carcinoma (TCGA)	unfavorable	0.000258

Disease associations

OMIM: gene MIM:605164 | disease phenotypes:

GenCC curated gene-disease

1 curated gene-disease records:

Disease	Classification	Inheritance	Records
complex neurodevelopmental disorder	Limited	Autosomal dominant

Genomics England panels (PanelApp)

Clinical diagnostic gene panels including this gene (1 panels, 0 green/diagnostic-grade). Confidence: green = diagnostic, amber = moderate.

1 panels:

Panel	Rating
Fetal anomalies	amber

Mondo (1): complex neurodevelopmental disorder (MONDO:0100038)

GWAS associations

3 associations:

Study	Trait	p-value
GCST003178_2	Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy	7e-7
GCST009391_698	Metabolite levels	3e-6
GCST009391_1500	Metabolite levels	9e-6

EFO canonical traits (from GWAS)

4 canonical traits:

EFO ID	Trait name
EFO:0000482	event free survival time
EFO:0007754	response to immunochemotherapy
EFO:0010457	Alpha ketoglutarate measurement
EFO:0007745	lactate measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (12): CHEMBL1937 (SINGLE PROTEIN), CHEMBL2093865 (PROTEIN FAMILY), CHEMBL2111429 (PROTEIN FAMILY), CHEMBL3430896 (PROTEIN FAMILY), CHEMBL3430897 (PROTEIN FAMILY), CHEMBL3885591 (PROTEIN COMPLEX), CHEMBL4296128 (PROTEIN-PROTEIN INTERACTION), CHEMBL4523988 (PROTEIN FAMILY), CHEMBL4630743 (PROTEIN-PROTEIN INTERACTION), CHEMBL5465383 (PROTEIN-PROTEIN INTERACTION)

Drugs by curated mechanism of action (ChEMBL)

Drugs whose curated ChEMBL mechanism of action targets the HDAC2 protein itself — single-protein targets only (drugs acting on a protein family or complex that merely includes it are excluded). Includes antibodies and oligonucleotides that bioactivity screening does not capture.

2 curated-mechanism drugs:

Drug	Modality	Max phase
VORINOSTAT	Small molecule	4
MOCETINOSTAT	Small molecule	2

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 678,468 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

41 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL98	VORINOSTAT	4	51,304
CHEMBL1487	ATORVASTATIN	4	69,270
CHEMBL408513	BELINOSTAT	4	8,184
CHEMBL487253	BENDAMUSTINE	4	31,460
CHEMBL325041	BORTEZOMIB	4	13,415
CHEMBL118	CELECOXIB	4	113,751
CHEMBL1213492	GIVINOSTAT	4	2,960
CHEMBL503	LOVASTATIN	4	93,071
CHEMBL483254	PANOBINOSTAT	4	12,172
CHEMBL1469	PHENYLBUTANOIC ACID	4	37,412
CHEMBL343448	ROMIDEPSIN	4	13,626
CHEMBL1746	SODIUM PHENYLBUTYRATE	4	5,678
CHEMBL109	VALPROIC ACID	4	66,702
CHEMBL2103863	ABEXINOSTAT	3	2,290
CHEMBL145	CAFFEIC ACID	3	36,727
CHEMBL140	CURCUMIN	3	95,185
CHEMBL51085	EBSELEN	3	13,356
CHEMBL27759	ENTINOSTAT	3	6,811
CHEMBL1851943	PRACINOSTAT	3	2,099
CHEMBL235191	TACEDINALINE	3	2,995
CHEMBL3621988	TUCIDINOSTAT	3
CHEMBL272980	MOCETINOSTAT	2
CHEMBL191482	AR-42	2
CHEMBL14227	BUTYRIC ACID	2
CHEMBL284616	CHLOROGENIC ACID	2
CHEMBL3693786	CITARINOSTAT	2
CHEMBL356066	DACINOSTAT	2
CHEMBL4283683	DOMATINOSTAT	2
CHEMBL3622533	FIMEPINOSTAT	2
CHEMBL1232461	MOLIBRESIB	2
CHEMBL1801250	NANATINOSTAT	2
CHEMBL2105763	QUISINOSTAT	2
CHEMBL2364628	RICOLINOSTAT	2
CHEMBL62381	SODIUM BUTYRATE	2
CHEMBL3989941	TINOSTAMUSTINE	2
CHEMBL5314582	BOCODEPSIN BESYLATE	1
CHEMBL598797	CUDC-101	1
CHEMBL96	GAMMA-AMINOBUTYRIC ACID	1
CHEMBL353581	PYROXAMIDE	1
CHEMBL609583	R-306465	1
CHEMBL99	TRICHOSTATIN	1

PharmGKB: 1 entry (CPIC guideline: no)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Histone deacetylases (HDACs)

Most potent curated ligand interactions (27 total), top 25:

Ligand	Action	Affinity	Parameter
romidepsin	Inhibition	10.42	pKi
santacruzamate A	Inhibition	9.92	pIC50
quisinostat	Inhibition	9.48	pIC50
trichostatin A	Inhibition	9.19	pKi
dacinostat	Inhibition	8.85	pKi
vorinostat	Inhibition	8.8	pKi
martinostat	Inhibition	8.7	pIC50
scriptaid	Inhibition	8.66	pKi
panobinostat	Inhibition	8.52	pEC50
CHR-3996	Inhibition	8.4	pIC50
fimepinostat	Inhibition	8.3	pIC50
CUDC-101	Inhibition	7.9	pIC50
mocetinostat	Inhibition	7.47	pKi
citarinostat	Inhibition	7.35	pIC50
ricolinostat	Inhibition	7.32	pIC50
givinostat	Inhibition	7.25	pEC50
apicidin	Inhibition	6.92	pEC50
belinostat	Inhibition	6.9	pEC50
ACY-738	Inhibition	6.89	pIC50
tacedinaline	Inhibition	6.82	pKi
suprastat	Inhibition	6.75	pIC50
BML-281	Inhibition	6.62	pIC50
domatinostat	Inhibition	6.43	pIC50
marbostat-100	Inhibition	6.11	pKi
entinostat	Inhibition	5.94	pEC50

Binding affinities (BindingDB)

4762 measured of 5783 human assays (5859 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
GNF-Pf-1011	IC50	0.001 nM
CHEMBL114184	IC50	0.02 nM
CHEMBL6148436	IC50	0.031 nM
(S)-N-((S)-1-(4-chloro-2-(4-fluorophenyl)-1H-imidazol-5-yl)-7-(oxazol-2-yl)-7-oxoheptyl)-6-ethyl-6-azaspiro[2.5]octane-1-carboxamide	IC50	0.049 nM	US-12331044: Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
CHEMBL4861467	IC50	0.05 nM
CHEMBL432618	IC50	0.062 nM
CHEMBL4237803	KI	0.075 nM
N-[(1S)-1-[5-(2-fluorophenyl)-1H-imidazol-2-yl]-7-(1,2-oxazol-3-yl)-7-oxoheptyl]-1-methylazetidine-3-carboxamide	IC50	0.08 nM	US-12331044: Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
CHEMBL321689	IC50	0.082 nM
CHEMBL6133082	IC50	0.082 nM
(S)-N-((S)-1-(4-chloro-2-(2-fluorophenyl)-1H-imidazol-5-yl)-7-(isoxazol-3-yl)-7-oxoheptyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide	IC50	0.083 nM	US-12331044: Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
CHEMBL4649205	IC50	0.085 nM
JNJ-26481585	IC50	0.1 nM
(2S)-N-[(1S)-1-[5-(2-fluorophenyl)-1H-imidazol-2-yl]-7-(1,2-oxazol-3-yl)-7-oxoheptyl]-6-methyl-6-azaspiro[2.5]octane-2-carboxamide	IC50	0.1 nM	US-12331044: Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
CHEMBL6145619	IC50	0.105 nM
CHEMBL432243	IC50	0.109 nM
CHEMBL113303	IC50	0.11 nM
CHEMBL4644038	IC50	0.11 nM
CHEMBL4876610	IC50	0.11 nM
CHEMBL4878197	IC50	0.11 nM
2-(dimethylamino)-N-[(1S)-1-[5-(2-fluorophenyl)-1H-imidazol-2-yl]-7-(1,2-oxazol-3-yl)-7-oxoheptyl]acetamide	IC50	0.11 nM	US-12331044: Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
CHEMBL6169315	IC50	0.116 nM
CHEMBL3622726	IC50	0.12 nM
(S)-N-(1-(4-chloro-2-(2-fluorophenyl)-1H-imidazol-5-yl)-7-(isoxazol-3-yl)-7-oxoheptyl)-1-methylazetidine-3-carboxamide	IC50	0.12 nM	US-12331044: Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
CHEMBL6174035	IC50	0.125 nM
CHEMBL3936651	IC50	0.13 nM
N-[(1S)-1-[5-(2-fluorophenyl)-1H-imidazol-2-yl]-7-(1,2-oxazol-3-yl)-7-oxoheptyl]-1-methylazetidine-2-carboxamide	IC50	0.13 nM	US-12331044: Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
(S)-N-(7-(isoxazol-3-yl)-1-(5-(7-methoxy-2-methylquinolin-6-yl)-1H-imidazol-2-yl)-7-oxoheptyl)-1-methylazetidine-3-carboxamide	IC50	0.13 nM	US-12331044: Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
N-[(1S)-1-[4-chloro-2-(4-fluorophenyl)-1H-imidazol-5-yl]-7-(1,3-oxazol-2-yl)-7-oxoheptyl]-2-(dimethylamino)acetamide	IC50	0.14 nM	US-12331044: Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
(1S)-6-ethyl-N-{(1S)-1-[5-(2- fluorophenyl)isoxazol-3-yl]-7- isoxazol-3-yl-7-oxoheptyl}-6- azaspiro[2.5]octane-1- carboxamide	IC50	0.14 nM	US-12331044: Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
(S)-N-((S)-1-(4-chloro-5-(4- fluorophenyl)-1H-imidazol-2-yl)-7- (isoxazol-3-yl)-7-oxoheptyl)-6- methyl-6-azaspiro[2.5]octane-1- carboxamide 2,3- dihydroxysuccinate	IC50	0.14 nM	US-12331044: Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
4sc-202	IC50	0.16 nM
CHEMBL4637689	IC50	0.16 nM
CHEMBL5218660	IC50	0.16 nM
N-[(1S)-1-[5-(2-fluorophenyl)-1H-imidazol-2-yl]-7-(5-methyl-1,2-oxazol-3-yl)-7-oxoheptyl]-1-methylazetidine-3-carboxamide	IC50	0.16 nM	US-12331044: Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
(S)-N-((S)-1-(4-cyano-2-(4- fluorophenyl)-1H-imidazol-5- yl)-7-(oxazol-2-yl)-7- oxoheptyl)-6-methyl-6- azaspiro[2.5]octane-1- carboxamide	IC50	0.16 nM	US-12331044: Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
CHEMBL4862152	IC50	0.17 nM
CHEMBL5177696	IC50	0.18 nM
2-(dimethylamino)-N-[(1S)-1-[5-(2-fluorophenyl)-1H-imidazol-2-yl]-7-(5-methyl-1,2-oxazol-3-yl)-7-oxoheptyl]acetamide	IC50	0.18 nM	US-12331044: Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
N-[(1S)-1-[5-(7-methoxy-2-methylquinolin-6-yl)-1H-imidazol-2-yl]-7-(5-methyl-1,2-oxazol-3-yl)-7-oxoheptyl]-6-methyl-6-azaspiro[2.5]octane-2-carboxamide	IC50	0.18 nM	US-12331044: Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
(S)-N-(7-(isoxazol-3-yl)-1-(5-(7-methoxy-2-methylquinolin-6-yl)oxazol-2-yl)-7-oxoheptyl)-1-methylazetidine-3-carboxamide	IC50	0.18 nM	US-12331044: Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
(S)-N-((S)-7-(isoxazol-3-yl)-1-(5-(7-methoxy-2-methylquinolin-6-yl)-1H-imidazol-2-yl)-7-oxoheptyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide	IC50	0.18 nM	US-12331044: Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
(S)-N-(1-(4-chloro-5-(4- fluorophenyl)-1H-imidazol-2-yl)-7- (isoxazol-3-yl)-7-oxoheptyl)-1- methylazetidine-3-carboxamide 2,3-dihydroxysuccinate	IC50	0.18 nM	US-12331044: Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
CHEMBL4532398	IC50	0.19 nM
CHEMBL4642518	IC50	0.19 nM
(S)-N-(1-(4-cyano-2-(4- fluorophenyl)-1H-imidazol-5- yl)-7-(oxazol-2-yl)-7- oxoheptyl)thiazole-5- carboxamide	IC50	0.19 nM	US-12331044: Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
(E)-N-hydroxy-3-[4-[[2-(1-methylindol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide	IC50	0.2 nM	US-10188756: Imaging histone deacetylases with a radiotracer using positron emission tomography
CHEMBL3317812	IC50	0.2 nM
CHEMBL1793991	IC50	0.2 nM
CHEMBL4634501	IC50	0.2 nM

ChEMBL bioactivities

6100 potent at pChembl≥5 of 6100 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.70	IC50	0.02	nM	CHEMBL114184
10.42	Ki	0.038	nM	ROMIDEPSIN
10.40	Ki	0.04	nM	CHEMBL2408247
10.22	Ki	0.06	nM	CHEMBL2408242
10.22	Ki	0.06	nM	QUISINOSTAT
10.21	IC50	0.062	nM	CHEMBL432618
10.09	IC50	0.082	nM	CHEMBL321689
10.00	Ki	0.1	nM	OXAMFLATIN
9.96	IC50	0.109	nM	CHEMBL432243
9.96	IC50	0.11	nM	CHEMBL113303
9.95	IC50	0.112	nM	CHEMBL3086767
9.92	Ki	0.12	nM	CHEMBL2408243
9.92	IC50	0.119	nM	CHEMBL3086767
9.92	Ki	0.12	nM	APICIDIN
9.89	Ki	0.13	nM	CHEMBL2408245
9.89	Ki	0.13	nM	CHEMBL99392
9.77	IC50	0.17	nM	CHEMBL5433552
9.75	IC50	0.179	nM	VORINOSTAT
9.74	IC50	0.18	nM	CHEMBL4080164
9.70	IC50	0.2	nM	CHEMBL2371007
9.70	IC50	0.2	nM	CHEMBL5274004
9.70	IC50	0.2	nM	CHEMBL5395502
9.70	IC50	0.2	nM	CHEMBL1793811
9.70	IC50	0.2	nM	CHEMBL1793991
9.70	IC50	0.2	nM	CHEMBL1793985
9.66	Ki	0.22	nM	CHEMBL2408246
9.64	Ki	0.23	nM	CHEMBL2408241
9.62	IC50	0.239	nM	CHEMBL6145619
9.60	Ki	0.25	nM	CHEMBL2408238
9.59	Ki	0.26	nM	CHEMBL2408237
9.52	IC50	0.3	nM	CHEMBL2370998
9.52	IC50	0.3	nM	QUISINOSTAT
9.52	IC50	0.3	nM	CHEMBL4861467
9.52	IC50	0.3	nM	CHEMBL5199116
9.52	IC50	0.3	nM	CHEMBL5170036
9.52	IC50	0.3	nM	CHEMBL1793822
9.51	IC50	0.31	nM	CHEMBL4878197
9.48	IC50	0.33	nM	QUISINOSTAT
9.46	Ki	0.35	nM	CHEMBL5413269
9.46	IC50	0.35	nM	VORINOSTAT
9.46	IC50	0.343	nM	CHEMBL6169315
9.43	IC50	0.373	nM	CHEMBL6174035
9.43	IC50	0.372	nM	CHEMBL6133082
9.42	IC50	0.38	nM	CHEMBL5618867
9.40	IC50	0.4	nM	CHEMBL2371000
9.40	IC50	0.4	nM	CHEMBL5220926
9.40	IC50	0.4	nM	CHEMBL1793816
9.38	Ki	0.42	nM	CHEMBL2408240
9.37	IC50	0.43	nM	CHEMBL4860000
9.33	IC50	0.47	nM	CHEMBL4641682

PubChem BioAssay actives

2915 with measured affinity, of 6100 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(E)-5-[4-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide	1236443: Inhibition of human HDAC2	ki	0.0001	uM
6-tert-butyl-2-hydroxycyclohepta-2,4,6-trien-1-one	760389: Inhibition of human recombinant HDAC2 by Michaelis-Menten equation analysis	ki	0.0001	uM
2-hydroxy-6-phenylcyclohepta-2,4,6-trien-1-one	760389: Inhibition of human recombinant HDAC2 by Michaelis-Menten equation analysis	ki	0.0001	uM
N-hydroxy-2-[4-(4-methylphenyl)sulfonylpiperazin-1-yl]-1,3-thiazole-5-carboxamide	1941741: Inhibition of HDAC (unknown origin)	ic50	0.0001	uM
N-hydroxy-2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide	1236443: Inhibition of human HDAC2	ki	0.0001	uM
(E)-N-hydroxy-3-[3-[methyl(2-phenylethyl)sulfamoyl]phenyl]prop-2-enamide	1949483: Inhibition of HDAC2 (unknown origin)	ic50	0.0002	uM
(E)-N-hydroxy-3-[3-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide;hydrochloride	1466055: Inhibition of recombinant human full length HDAC2 using Fluor-de-Lys as substrate after 60 mins by spectrofluorimetric analysis	ic50	0.0002	uM
7-[4-[[4-[3-(tert-butylsulfamoyl)anilino]-5-methylpyrimidin-2-yl]amino]-2-fluorophenoxy]-N-hydroxyheptanamide	2031064: Inhibition of HDAC in human HeLa cells nuclear extract incubated for 30 mins by multiplate reader analysis	ic50	0.0002	uM
7-[4-[[4-[3-(tert-butylsulfamoyl)anilino]-5-methylpyrimidin-2-yl]amino]phenoxy]-N-hydroxyheptanamide	2031064: Inhibition of HDAC in human HeLa cells nuclear extract incubated for 30 mins by multiplate reader analysis	ic50	0.0002	uM
2-hydroxy-3-phenylcyclohepta-2,4,6-trien-1-one	760389: Inhibition of human recombinant HDAC2 by Michaelis-Menten equation analysis	ki	0.0003	uM
(2S)-6-cyclobutyl-N-[(1S)-1-[5-(7-methoxy-2-methylquinolin-6-yl)-1H-imidazol-2-yl]-7-oxononyl]-6-azaspiro[2.5]octane-2-carboxamide	1916028: Inhibition of human full length FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 cells using BML-KI104 as substrate preincubated for 3 hrs followed by substrate addition measured after 60 mins by modified FLUOR DE LYS assay	ic50	0.0003	uM
(3S,6S)-12-methoxy-6-(6-oxooctyl)-5,8,18,27,34-pentazahexacyclo[25.2.2.17,10.111,15.114,18.01,3]tetratriaconta-7,9,11,13,15(33),16-hexaene-4,32-dione	1754653: Inhibition of HDAC2 (unknown origin)	ic50	0.0003	uM
(2S)-6-(cyclopropylmethyl)-N-[(1S)-1-[5-(7-methoxyquinolin-6-yl)-1H-imidazol-2-yl]-7-oxononyl]-6-azaspiro[2.5]octane-2-carboxamide	1768794: Inhibition of human recombinant FLAG-tagged HDAC2 expressed in Sf9 cells incubated for 30 mins by Fluor De Lys assay	ic50	0.0003	uM
(2S)-6-(cyclopropylmethyl)-N-[(1S)-1-[5-(7-methoxy-2-methylquinolin-6-yl)-1H-imidazol-2-yl]-7-oxononyl]-6-azaspiro[2.5]octane-2-carboxamide	1916028: Inhibition of human full length FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 cells using BML-KI104 as substrate preincubated for 3 hrs followed by substrate addition measured after 60 mins by modified FLUOR DE LYS assay	ic50	0.0003	uM
(9S,12R)-3-[(2S)-butan-2-yl]-9-(6-hydroxy-5-oxoheptyl)-6-[(1-methoxyindol-3-yl)methyl]-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone	1847765: Inhibition of HDAC (unknown origin)	ic50	0.0003	uM
(9S,12R)-3-[(2S)-butan-2-yl]-6-(1H-indol-3-ylmethyl)-9-(5-oxoheptyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone	1847765: Inhibition of HDAC (unknown origin)	ic50	0.0003	uM
(2S)-N-[(1S)-1-[5-(2-cyclopropyl-7-methoxyquinolin-6-yl)-1H-imidazol-2-yl]-7-oxononyl]-6-(cyclopropylmethyl)-6-azaspiro[2.5]octane-2-carboxamide	1916028: Inhibition of human full length FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 cells using BML-KI104 as substrate preincubated for 3 hrs followed by substrate addition measured after 60 mins by modified FLUOR DE LYS assay	ic50	0.0003	uM
(2S)-6-(cyclopropylmethyl)-N-[(1S)-1-[5-(2-ethyl-7-methoxyquinolin-6-yl)-1H-imidazol-2-yl]-7-oxononyl]-6-azaspiro[2.5]octane-2-carboxamide	1916028: Inhibition of human full length FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 cells using BML-KI104 as substrate preincubated for 3 hrs followed by substrate addition measured after 60 mins by modified FLUOR DE LYS assay	ic50	0.0003	uM
(2S)-6-ethyl-N-[(1S)-1-[5-(7-methoxy-2-methylquinolin-6-yl)-1H-imidazol-2-yl]-7-oxononyl]-6-azaspiro[2.5]octane-2-carboxamide	1916028: Inhibition of human full length FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 cells using BML-KI104 as substrate preincubated for 3 hrs followed by substrate addition measured after 60 mins by modified FLUOR DE LYS assay	ic50	0.0004	uM
(3S,6S)-6-(6-oxooctyl)-5,8,18,27,34-pentazahexacyclo[25.2.2.17,10.111,15.114,18.01,3]tetratriaconta-7,9,11(33),12,14,16-hexaene-4,32-dione	1754653: Inhibition of HDAC2 (unknown origin)	ic50	0.0004	uM
(5R,8S,11S)-5-methyl-11-[(E)-4-[[(E)-4-[(5R,8S,11S)-5-methyl-6,9,13-trioxo-8-propan-2-yl-10-oxa-3,17-dithia-7,14,19,20-tetrazatricyclo[14.2.1.12,5]icosa-1(18),2(20),16(19)-trien-11-yl]but-3-enyl]disulfanyl]but-1-enyl]-8-propan-2-yl-10-oxa-3,17-dithia-7,14,19,20-tetrazatricyclo[14.2.1.12,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione	1188978: Inhibition of HDAC2 (unknown origin) incubated for 30 mins in presence of BSA and DTT by fluorescence assay	ic50	0.0005	uM
(E)-N-hydroxy-3-[4-[2-(1-methylindol-4-yl)ethylsulfamoyl]phenyl]prop-2-enamide	1466055: Inhibition of recombinant human full length HDAC2 using Fluor-de-Lys as substrate after 60 mins by spectrofluorimetric analysis	ic50	0.0005	uM
N-[(1S)-1-[5-(2-fluorophenyl)-1H-imidazol-2-yl]-7-(1,2-oxazol-3-yl)-7-oxoheptyl]-1-methylazetidine-3-carboxamide	1664941: Inhibition of full length human recombinant FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 cells using FLUOR DE LYS as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence based assay	ic50	0.0005	uM
(2R)-N-[4-[1-[7-(hydroxyamino)-7-oxoheptyl]-4-morpholin-4-ylpyrazolo[5,4-d]pyrimidin-6-yl]phenyl]-2-methylmorpholine-4-carboxamide	1614127: Inhibition of recombinant full length human HDAC2 expressed in baculovirus expression system using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence assay	ic50	0.0006	uM
(2S)-N-[(1S)-1-[5-(7-methoxy-2-methylquinolin-6-yl)-1H-imidazol-2-yl]-7-oxononyl]-6-propan-2-yl-6-azaspiro[2.5]octane-2-carboxamide	1916028: Inhibition of human full length FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 cells using BML-KI104 as substrate preincubated for 3 hrs followed by substrate addition measured after 60 mins by modified FLUOR DE LYS assay	ic50	0.0006	uM
(2S)-N-[(1S)-1-[5-(2-cyclopropyl-7-methoxyquinolin-6-yl)-1H-imidazol-2-yl]-7-oxononyl]-6-methyl-6-azaspiro[2.5]octane-2-carboxamide	1916028: Inhibition of human full length FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 cells using BML-KI104 as substrate preincubated for 3 hrs followed by substrate addition measured after 60 mins by modified FLUOR DE LYS assay	ic50	0.0006	uM
(2S)-6-(cyclopropylmethyl)-N-[(1S)-1-[5-(2-methoxyquinolin-3-yl)-1H-imidazol-2-yl]-7-oxononyl]-6-azaspiro[2.5]octane-2-carboxamide	1662501: Inhibition of HDAC2 (unknown origin)	ic50	0.0007	uM
(2S)-6-(cyclopropylmethyl)-N-[(1S)-1-[5-(7-methoxy-2-methylquinolin-6-yl)-1,3-oxazol-2-yl]-7-oxononyl]-6-azaspiro[2.5]octane-2-carboxamide	1768794: Inhibition of human recombinant FLAG-tagged HDAC2 expressed in Sf9 cells incubated for 30 mins by Fluor De Lys assay	ic50	0.0007	uM
(2S)-6-ethyl-N-[(1S)-1-[5-(7-methoxy-1-methyl-2-oxoquinolin-6-yl)-1H-imidazol-2-yl]-7-oxononyl]-6-azaspiro[2.5]octane-2-carboxamide	1916028: Inhibition of human full length FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 cells using BML-KI104 as substrate preincubated for 3 hrs followed by substrate addition measured after 60 mins by modified FLUOR DE LYS assay	ic50	0.0007	uM
(2S)-N-[(1S)-1-[5-(2,7-dimethylquinolin-6-yl)-1H-imidazol-2-yl]-7-oxononyl]-6-methyl-6-azaspiro[2.5]octane-2-carboxamide	1916028: Inhibition of human full length FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 cells using BML-KI104 as substrate preincubated for 3 hrs followed by substrate addition measured after 60 mins by modified FLUOR DE LYS assay	ic50	0.0007	uM
2-hydroxy-3-(4-methoxyphenyl)cyclohepta-2,4,6-trien-1-one	760389: Inhibition of human recombinant HDAC2 by Michaelis-Menten equation analysis	ki	0.0008	uM
N-[(1S)-1-[5-(2-fluorophenyl)-1,3-oxazol-2-yl]-7-(1,2-oxazol-3-yl)-7-oxoheptyl]-1-methylazetidine-3-carboxamide	1664941: Inhibition of full length human recombinant FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 cells using FLUOR DE LYS as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence based assay	ic50	0.0008	uM
N-[(1S)-1-[5-(2-fluorophenyl)-1H-imidazol-2-yl]-7-(5-methyl-1,2-oxazol-3-yl)-7-oxoheptyl]-1-methylazetidine-3-carboxamide	1664941: Inhibition of full length human recombinant FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 cells using FLUOR DE LYS as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence based assay	ic50	0.0008	uM
tert-butyl (2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-[[(E)-4-[(5R,8S,11S)-5-methyl-6,9,13-trioxo-8-propan-2-yl-10-oxa-3,17-dithia-7,14,19,20-tetrazatricyclo[14.2.1.12,5]icosa-1(18),2(20),16(19)-trien-11-yl]but-3-enyl]disulfanyl]propanoate	1188978: Inhibition of HDAC2 (unknown origin) incubated for 30 mins in presence of BSA and DTT by fluorescence assay	ic50	0.0009	uM
(E)-N-hydroxy-3-[4-[2-(1H-indol-4-yl)ethylsulfamoyl]phenyl]prop-2-enamide	1466055: Inhibition of recombinant human full length HDAC2 using Fluor-de-Lys as substrate after 60 mins by spectrofluorimetric analysis	ic50	0.0009	uM
(3S,6S,22E)-6-(6-oxooctyl)-5,8,20,25,31-pentazaheptacyclo[23.2.2.17,10.111,15.01,3.014,19.016,20]hentriaconta-7,9,11(30),12,14,22-hexaen-4-one	1754653: Inhibition of HDAC2 (unknown origin)	ic50	0.0009	uM
N-hydroxy-2-[4-[(E)-1-hydroxy-4-phenylbut-3-en-2-yl]piperazin-1-yl]pyrimidine-5-carboxamide	454842: Inhibition of HDAC in human HeLa cells extractt	ic50	0.0010	uM
2-[4-[(E)-4-(4-fluorophenyl)-1-hydroxybut-3-en-2-yl]piperazin-1-yl]-N-hydroxypyrimidine-5-carboxamide	454842: Inhibition of HDAC in human HeLa cells extractt	ic50	0.0010	uM
(3S,6R,9S,12R)-3-[(2S)-butan-2-yl]-6-[(1-methoxyindol-2-yl)methyl]-9-(6-oxooctyl)-1,4,10-triazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone	1622995: Inhibition of HDAC (unknown origin)	ic50	0.0010	uM
tert-butyl 4-[[(5R,8S,11S)-5-methyl-6,9,13-trioxo-11-[(E)-4-sulfanylbut-1-enyl]-10-oxa-3,17-dithia-7,14,19,20-tetrazatricyclo[14.2.1.12,5]icosa-1(18),2(20),16(19)-trien-8-yl]methyl]imidazole-1-carboxylate	1185953: Inhibition of HDAC2 (unknown origin) incubated at 37 degC for 30 mins	ic50	0.0011	uM
(5R,8S,11S)-8-[(4-hydroxyphenyl)methyl]-5-methyl-11-[(E)-4-sulfanylbut-1-enyl]-10-oxa-3,17-dithia-7,14,19,20-tetrazatricyclo[14.2.1.12,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione	1185953: Inhibition of HDAC2 (unknown origin) incubated at 37 degC for 30 mins	ic50	0.0011	uM
N’-[(5-bromothiophen-2-yl)methyl]-N-hydroxy-N’-[4-(2-morpholin-4-ylethoxy)phenyl]heptanediamide	1927783: Inhibition of HDAC2 (unknown origin)	ic50	0.0011	uM
(2S)-6-ethyl-N-[(1S)-1-[5-(7-methoxy-2-methylquinolin-6-yl)-1,3-oxazol-2-yl]-7-oxononyl]-6-azaspiro[2.5]octane-2-carboxamide	1916028: Inhibition of human full length FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 cells using BML-KI104 as substrate preincubated for 3 hrs followed by substrate addition measured after 60 mins by modified FLUOR DE LYS assay	ic50	0.0011	uM
(2S)-N-[(1S)-1-[5-(2-cyclopropylquinolin-6-yl)-1H-imidazol-2-yl]-7-oxononyl]-6-methyl-6-azaspiro[2.5]octane-2-carboxamide	1916028: Inhibition of human full length FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 cells using BML-KI104 as substrate preincubated for 3 hrs followed by substrate addition measured after 60 mins by modified FLUOR DE LYS assay	ic50	0.0011	uM
(2S)-N-[(1S)-1-[5-(9H-carbazol-3-yl)-1H-imidazol-2-yl]-7-oxononyl]-6-methyl-6-azaspiro[2.5]octane-2-carboxamide	1694524: Inhibition of HDAC2 (unknown origin) using compound purified by traditional preparative HPLC work-flow	ic50	0.0011	uM
(3S,6R,9S,12R)-6,9-dimethyl-3-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone	1972804: Binding affinity to HDAC2 (unknown origin) assessed as inhibition constant	ki	0.0012	uM
N-hydroxy-5-[5-[1-(3,4,5-trimethoxyphenyl)-9H-pyrido[3,4-b]indol-3-yl]-1,3,4-oxadiazol-2-yl]pentanamide	1890511: Inhibition of HDAC2 (unknown origin)	ic50	0.0012	uM
(E)-N-hydroxy-3-[4-[[2-(1-(111C)methylindol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide	1949483: Inhibition of HDAC2 (unknown origin)	ic50	0.0012	uM
(2S)-N-[(1S)-1-[5-(7-methoxy-2-methylquinolin-6-yl)-1,3-oxazol-2-yl]-7-oxononyl]-6-methyl-6-azaspiro[2.5]octane-2-carboxamide	1916028: Inhibition of human full length FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 cells using BML-KI104 as substrate preincubated for 3 hrs followed by substrate addition measured after 60 mins by modified FLUOR DE LYS assay	ic50	0.0013	uM
(5R,8S,11S)-8-(1H-imidazol-5-ylmethyl)-5-methyl-11-[(E)-4-sulfanylbut-1-enyl]-10-oxa-3,17-dithia-7,14,19,20-tetrazatricyclo[14.2.1.12,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione	1185953: Inhibition of HDAC2 (unknown origin) incubated at 37 degC for 30 mins	ic50	0.0014	uM

CTD chemical–gene interactions

83 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	increases expression, decreases activity, decreases reaction	4
Valproic Acid	increases degradation, decreases expression, increases reaction, decreases activity	4
sodium arsenite	decreases reaction, increases expression, decreases expression, affects cotreatment, increases abundance	3
Vorinostat	decreases expression, affects binding, decreases activity, affects cotreatment	3
bisphenol A	affects expression, decreases expression	2
sulforaphane	affects cotreatment, decreases expression	2
hydroquinone	increases expression, decreases reaction	2
benzyloxycarbonylleucyl-leucyl-leucine aldehyde	decreases expression, decreases reaction, increases degradation, increases ubiquitination, affects cotreatment	2
Resveratrol	increases metabolic processing, affects cotreatment, increases expression	2
Arsenic Trioxide	affects expression, increases methylation	2
Air Pollutants	decreases expression, increases abundance, increases expression	2
Arsenic	decreases methylation, increases abundance, affects cotreatment, increases expression	2
Benzo(a)pyrene	affects methylation, increases expression	2
Curcumin	decreases expression, decreases activity, decreases reaction, increases degradation	2
Doxorubicin	affects binding, decreases reaction, increases reaction, decreases expression	2
Rotenone	decreases expression	2
Particulate Matter	decreases expression, increases abundance, increases expression	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
Batroxase, Bothrops atrox	increases expression	1
bisphenol F	increases expression	1
TAK-243	increases sumoylation	1
dicrotophos	decreases expression	1
honokiol	affects binding, decreases activity	1
4-biphenylamine	decreases expression, decreases reaction	1
deoxynivalenol	increases expression	1
methoxyacetic acid	decreases activity	1
malealdehyde	affects expression	1
3,3’-diindolylmethane	decreases expression	1
butyraldehyde	decreases expression	1

ChEMBL screening assays

2775 unique, capped per target: 2743 binding, 24 admet, 7 functional, 1 toxicity

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1002514	Binding	Inhibition of human C-terminal FLAG-tagged HDAC2 in HEK293 cells	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties. — *J Med Chem*
CHEMBL3860977	ADMET	Inhibition of HDAC2 (unknown origin)	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer’s Disease. — *J Med Chem*
CHEMBL5049469	Functional	In vivo inhibition of HDAC2 in HEL cells xenografted in BALB/C mouse assessed as upregulation of acetyl-H4 levels at 5 to 10 mg/kg by immunohistochemical staining method	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy. — *J Med Chem*

Cellosaurus cell lines

15 cell lines: 8 cancer cell line, 4 transformed cell line, 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A2M0	SEES3-1V human HDAC2, clone1	Embryonic stem cell	Male
CVCL_A2M1	SEES3-1V human HDAC2, clone2	Embryonic stem cell	Male
CVCL_A2M2	SEES3-1V human HDAC2, clone3	Embryonic stem cell	Male
CVCL_B2YJ	Abcam HEK293T HDAC2 KO 1	Transformed cell line	Female
CVCL_B2YK	Abcam HEK293T HDAC2 KO 2	Transformed cell line	Female
CVCL_B2YL	Abcam HEK293T HDAC2 KO 3	Transformed cell line	Female
CVCL_B8H7	Abcam HCT 116 HDAC2 KO	Cancer cell line	Male
CVCL_B8WK	Abcam MCF-7 HDAC2 KO	Cancer cell line	Female
CVCL_B9JH	Abcam A-549 HDAC2 KO	Cancer cell line	Male
CVCL_D7R5	Ubigene A-549 HDAC2 KO	Cancer cell line	Male

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 212 trials:

NCT	Phase	Status	Title
NCT04586348	Phase 4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	Phase 4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	Phase 3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	Phase 3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	Phase 3	RECRUITING	Reducing Missed Appointments
NCT07377032	Phase 3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	Phase 2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	Phase 2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	Phase 2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	Phase 1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	Phase 1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	Phase 1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT06310681	Not specified	COMPLETED	Pilot Testing of a Co-adapted Group Programme for Parents/Carers of Children With Complex Neurodisability
NCT07303049	Not specified	NOT_YET_RECRUITING	Cognitive Benefit of Intensive Rehabilitation Using Rhythmic Music Training in Children With Complex Neurodevelopmental Disorder
NCT01783041	Phase 2/3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	Phase 2/3	COMPLETED	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	Early Phase 1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	COMPLETED	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice
NCT03381027	Not specified	COMPLETED	BABY SMART (Study of Massage Therapy, Sleep And neurodevelopMenT)
NCT03388294	Not specified	COMPLETED	Evaluation of a Novel Intervention for Infants At Risk for Neurodevelopmental Disorders
NCT03410810	Not specified	UNKNOWN	Childhood Outcomes of Preterm Brain Abnormalities
NCT03492060	Not specified	RECRUITING	Longitudinal Study of Neurogenetic Disorders
NCT03577756	Not specified	COMPLETED	Neurodevelopmental Assessment of Infants With Cystic Fibrosis
NCT03654248	Not specified	COMPLETED	Let’s Get Organized in Adult Psychiatric/habilitation Care
NCT03659279	Not specified	COMPLETED	Let’s Get Organized Feasibility Study
NCT03722615	Not specified	COMPLETED	Epidemiology of Congenital Cytomegalovirus in a High HIV Prevalence Setting, South Africa
NCT03770832	Not specified	ACTIVE_NOT_RECRUITING	Wearable Sensors and Video Recordings to Monitor Motor Development
NCT03830879	Not specified	RECRUITING	Shenzhen Birth Cohort Study
NCT03835689	Not specified	COMPLETED	Strongest FamiliesTM Neurodevelopmental
NCT03882788	Not specified	COMPLETED	The Effect of Anesthesia on Neurodevelopmental Outcome (NDO)
NCT03922087	Not specified	COMPLETED	No-worry Baby Project
NCT03977259	Not specified	ACTIVE_NOT_RECRUITING	Targeting Human Milk Fortification to Improve Preterm Infant Growth and Brain Development
NCT04043572	Not specified	UNKNOWN	The Biomarkers of Neurological Disease in Utero Study
NCT04096430	Not specified	RECRUITING	Evaluation of Effectiveness of Child-oriented Goal-setting in Paediatric Rehabilitation (the ENGAGE Approach)
NCT04108273	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children
NCT04201509	Not specified	COMPLETED	Validity of Neurocognitive Assessment Methods in Childhood ADHD

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for HDAC2 across ~30M SureChEMBL compounds — explore on Sugi Predict.